USRE48841E1 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators - Google Patents

Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators Download PDF

Info

Publication number
USRE48841E1
USRE48841E1 US16/391,791 US201016391791A USRE48841E US RE48841 E1 USRE48841 E1 US RE48841E1 US 201016391791 A US201016391791 A US 201016391791A US RE48841 E USRE48841 E US RE48841E
Authority
US
United States
Prior art keywords
phenyl
triazol
pyrrol
carbonyl
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/391,791
Other languages
English (en)
Inventor
Wenying Chai
Michael A. Letavic
Kiev S. Ly
Daniel J. Pippel
Dale A. Rudolph
Kathleen C. Sappey
Brad M. Savall
Chandravadan R. Shah
Brock T. Shireman
Akinola Soyode-Johnson
Emily M. Stocking
Devin M. Swanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to US16/391,791 priority Critical patent/USRE48841E1/en
Application granted granted Critical
Publication of USRE48841E1 publication Critical patent/USRE48841E1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to certain disubstituted octahydropyrrolo[3,4-c]pyrrole compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them for the modulation of the orexin receptor and for the treatment of disease states, disorders, and conditions mediated by orexin receptor activity.
  • Orexin (or hypocretin) signaling is mediated by two receptors and two peptide agonists.
  • the two orexin peptides herein after referred to as orexins, bind to two high affinity receptors, termed orexin-1 and orexin-2 receptors.
  • the orexin-1 receptor is selective in favor of orexin A, while the orexin-2 receptor binds both orexins with similar affinities.
  • the orexins are cleavage products of the same gene, prepro orexin.
  • neuronal neurosci. the precursor from which orexin is produced, are found in the periformical nucleus, the dorsal hypothalamus and the lateral hypothalamus (C. Peyron et al., J. Neurosci., 1998, 18(23), 9996-10015). Orexinergic cells in these nuclei project to many areas of the brain, extending rostrally to the olfactory bulbs and caudally to the spinal cord (van den Pol, A. N. et al., J. Neuroscience., 1999, 19(8), 3171-3182).
  • TMN tuberomammillary nucleus
  • narcolepsy Rodents whose prepro orexin gene has been knocked out, or whose orexigenic neurons have been lesioned, display altered sleep/wake cycles similar to narcolepsy (Chemelli et al., Cell 1999, 98, 437-451; Hara et al., 2001, supra). Dog models of narcolepsy have been shown to have mutant or non-functional orexin-2 receptors (Lin et al., Cell 1999, 98, 365-376). Human narcolepsy appears to be linked to deficient orexin signaling, likely related to immune ablation of orexinergic neurons in the lateral hypothalamus (Mignot et al., Am. J. Hum. Genet.
  • EEG data indicates that orexin-2 may be more important than orexin-1 in the modulation of sleep/wake (P. Malherbe et al., Molecular Pharmacology (2009) 76(3):618-31; C. Dugovic et al., J. Pharmacol. Exp. Ther., 2009, 330(1), 142-151).
  • Disorders of the sleep-wake cycle are therefore likely targets for orexin-2 receptor antagonist therapy. Examples of such disorders include sleep-wake transition disorders, insomnia, restless legs syndrome, jet-lag, disturbed sleep, and sleep disorders secondary to neurological disorders (e.g., manias, depressions, manic depression, schizophrenia, and pain syndromes (e.g., fibromyalgia, neuropathic pain).
  • orexin-2 modulators may be useful to treat various neurological disorders; e.g., agonists or up-regulators to treat catatonia, antagonists or down-regulators to treat Parkinson's disease, Tourette's syndrome, anxiety, delerium and dementias.
  • nicotine J. K. Kane et al., Endocrinology, 2000, 141(10), 3623-3629; J. K. Kane et al., Neurosci. Lett., 2001, 298(1), 1-4), morphine (D.
  • Orexins and their receptors have been found in both the myenteric and submucosal plexus of the enteric nervous system, where orexins have been shown to increase motility in vitro (Kirchgessner & Liu, Neuron 1999, 24, 941-951) and to stimulate gastric acid secretion in vitro (Takahashi et al., Biochem. Biophys. Res. Comm. 1999, 254, 623-627).
  • Orexin mediated effects on the gut may be driven by a projection via the vagus nerve (van den Pol, 1999, supra), as vagotomy or atropine prevent the effect of an intracerebroventricular injection of orexin on gastric acid secretion (Takahashi et al., 1999, supra).
  • Orexin receptor antagonists or other down-regulators of orexin receptor-mediated systems are therefore potential treatments for ulcers, irritable bowel syndrome, diarrhea and gastroesophageal reflux.
  • Body weight may also be affected by orexin-mediated regulation of appetite and metabolism (T. Sakurai et al., Cell, 1998, 92(4), 573-585; T. Sakurai, Reg. Pept., 1999, 85(1), 25-30).
  • Orexin receptor antagonists therefore are likely to be useful in treatment of overweight or obesity and conditions related to overweight or obesity, such as insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins and osteoarthritis.
  • orexin receptor agonists are likely to be useful in treatment of underweight and related conditions such as hypotension, bradycardia, ammenorrhea and related infertility, and eating disorders such as anorexia and bulimia.
  • Intracerebroventricularly administered orexins have been shown to increase mean arterial pressure and heart rate in freely moving (awake) animals (Samson et al., Brain Res. 1999, 831, 248-253; Shirasaka et al., Am. J. Physiol. 1999, 277, R1780-R1785) and in urethane-anesthetized animals (Chen et al., Am. J. Physiol. 2000, 278, R692-R697), with similar results.
  • Orexin receptor agonists may therefore be candidates for treatment of hypotension, bradycardia and heart failure related thereto, while orexin receptor antagonists may be useful for treatment of hypertension, tachycardia and other arrhythmias, angina pectoris and acute heart failure.
  • modulators of the orexin-2 receptor will be of great advantage in the development of therapeutic agents for the treatment of a wide variety of disorders that are mediated through these receptor systems.
  • N-aroyl cyclic amine derivatives International Publication No. WO2003002561, Jan. 9, 3003
  • ethylene diamine derivatives International Publication No. WO2003051872, Jun. 26, 2003
  • sulfonylamino-acetic acid derivatives International Publication No. WO2004033418, Apr. 22, 2004
  • N-aryl acetyl cyclic amine derivatives International Publication No. WO2004041791, May 21, 2004
  • diazepan derivatives International Publication No. WO2007126935, Nov. 8, 2007
  • amidoethylthioether derivatives International Publication No. WO2007126934, Nov.
  • Substituted diaza-bicyclic compounds have been reported as active central nervous system agents (International Publication No. WO2001081347, Nov. 1, 2001; US2002/0019388, Feb. 14, 2002), ⁇ 7 acetylcholine receptor modulators (US2005/101602, May 12, 2005; US2005/0065178, Mar. 24, 2005 and Frost et al, Journal of Medicinal Chemistry, 2006, 49(26), 7843-7853), proline transporter inhibitors for the treatment of cognitive impairment (WO2008067121, Jun. 5, 2008) and for improving cognition (WO 2006 124897, Nov. 23, 2006 and US20060258672, Nov.
  • the invention is directed to a chemical entity of Formula (I):
  • compositions of Formula (I) or Formula (II) are provided by pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), and pharmaceutically active metabolites of compounds of Formula (I) or Formula (II).
  • the compound of Formula (I) or Formula (II) is a compound selected from those species described or exemplified in the detailed description below.
  • the invention relates to pharmaceutical compositions for treating a disease, disorder, or medical condition mediated by orexin receptor activity, comprising an effective amount of at least one chemical entity selected from compounds of Formula (I) or Formula (II), pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), and pharmaceutically active metabolites of Formula (I) or Formula (II).
  • compositions according to the invention may further comprise one or more pharmaceutically acceptable excipients.
  • the chemical embodiments of the present invention are useful as orexin receptor modulators.
  • the invention is directed to a method for modulating orexin receptor activity, including when such receptor is in a subject, comprising exposing orexin receptor to an effective amount of at least one chemical entity selected from compounds of Formula (I) or Formula (II), pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), and pharmaceutically active metabolites of compounds of Formula (I) or Formula (II).
  • the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by orexin receptor activity, comprising administering to the subject in need of such treatment an effective amount of at least one chemical entity selected from compounds of Formula (I) or Formula (II), pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), and pharmaceutically active metabolites of compounds of Formula (I) or Formula (II). Additional embodiments of methods of treatment are set forth in the detailed description.
  • method of studying isotopically labeled compounds in metabolic studies preferably with 14 C
  • reaction kinetic studies with, for example 2 H or 3 H
  • detection or imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)
  • drug or substrate tissue distribution assays or in radioactive treatment of patients.
  • an 18 F or 11 C labeled compound may be particularly preferred for PET or an I 123 for SPECT studies.
  • An object of the present invention is to overcome or ameliorate at least one of the disadvantages of the conventional methodologies and/or prior art, or to provide a useful alternative thereto. Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.
  • FIG. 1 is a Powder X-Ray Diffraction of an exemplied compound X
  • alkyl refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain.
  • alkyl groups include methyl (Me, which also may be structurally depicted by the symbol, “/”), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
  • alkoxy includes a straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule.
  • Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on.
  • Aminoalkyl”, “thioalkyl”, and “sulfonylalkyl” are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO 2 .
  • cyano refers to the group —CN.
  • cycloalkyl refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle.
  • Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:
  • heterocycloalkyl refers to a monocyclic ring structure that is saturated or partially saturated and has from 4 to 7 ring atoms per ring structure selected from carbon atoms and up to two heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the ring structure may optionally contain up to two oxo groups on sulfur ring members.
  • Illustrative entities, in the form of properly bonded moieties include:
  • aryl refers to a monocyclic, or fused or spiro polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having from 3 to 12 ring atoms per ring. (Carbon atoms in aryl groups are sp 2 hybridized.) Illustrative examples of aryl groups include the following moieties:
  • heteroaryl refers to a monocyclic, fused bicyclic, or fused polycyclic aromatic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 12 ring atoms per heterocycle.
  • heteroaryl groups include the following entities, in the form of properly bonded moieties:
  • heteroaryl, cycloalkyl, aryl and heterocycloalkyl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.
  • halogen represents chlorine, fluorine, bromine or iodine.
  • halo represents chloro, fluoro, bromo or iodo.
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.
  • buffered solution or “buffer” solution are used herein interchangeably according to their standard meaning. Buffered solutions are used to control the pH of a medium, and their choice, use, and function is known to those of ordinary skill in the art. See, for example, G. D. Considine, ed., Van Nostrand's Encyclopedia of Chemistry, p. 261, 5 th ed. (2005), describing, inter alia, buffer solutions and how the concentrations of the buffer constituents relate to the pH of the buffer. See also Handbook of Chemistry and Physics, 84 th ed., pp. 8-37 to 8-44. For example, a buffered solution is obtained by adding MgSO 4 and NaHCO 3 to a solution in a 10:1 w/w ratio to maintain the pH of the solution at about 7.5.
  • any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
  • compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula.
  • any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
  • certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers.
  • any formula given herein is intended to refer also to hydrates, solvates, and polymorphs of such compounds, and mixtures thereof, even if such forms are not listed explicitly.
  • Certain compounds of Formula (I) or Formula (II) or pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II) may be obtained as solvates.
  • Solvates include those formed from the interaction or complexation of compounds of the invention with one or more solvents, either in solution or as a solid or crystalline form. In some embodiments, the solvent is water and then the solvates are hydrates.
  • certain crystalline forms of compounds of Formula (I) or Formula (II) or pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II) may be obtained as co-crystals.
  • compounds of Formula (I) or Formula (II) were obtained in a crystalline form.
  • crystalline forms of compounds of Formula (I) or Formula (II) were cubic in nature.
  • pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II) were obtained in a crystalline form.
  • compounds of Formula (I) or Formula (II) were obtained in one of several polymorphic forms, as a mixture of crystalline forms, as a polymorphic form, or as an amorphous form.
  • compounds of Formula (I) or Formula (II) convert in solution between one or more crystalline forms and/or polymorphic forms.
  • references to a chemical entity herein stands for a reference to any one of: (a) the actually recited form of such chemical entity, and (b) any of the forms of such chemical entity in the medium in which the compound is being considered when named.
  • reference herein to a compound such as R—COOH encompasses reference to any one of, for example, R—COOH (s) , R—COOH (sol) , and R—COO ⁇ (sol) .
  • R—COOH (s) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation
  • R—COOH (sol) refers to the undissociated form of the compound in a solvent
  • R—COO ⁇ (sol) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R—COOH, from a salt thereof, or from any other entity that yields R—COO ⁇ upon dissociation in the medium being considered.
  • an expression such as “exposing an entity to compound of formula R—COOH” refers to the exposure of such entity to the form, or forms, of the compound R—COOH that exists, or exist, in the medium in which such exposure takes place.
  • an expression such as “reacting an entity with a compound of formula R—COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R—COOH that exists, or exist, in the medium in which such reacting takes place.
  • a zwitterionic compound is encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form.
  • Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names.
  • the name zwitterion is assigned the name identification CHEBI:27369 by the Chemical Entities of Biological Inerest (ChEBI) dictionary of molecular entities.
  • a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign.
  • aminoethanoic acid (the amino acid glycine) has the formula H 2 NCH 2 COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion + H 3 NCH 2 COO ⁇ .
  • Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 125 I, respectively.
  • Such isotopically labeled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or 11 C labeled compound may be particularly preferred for PET or an I 123 for SPECT studies.
  • substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
  • Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof.
  • substituent S example is one of S 1 , S 2 , and S 3
  • this listing refers to embodiments of this invention for which S example is S 1 ; S example is S 2 ; S example is S 3 ; S example is one of S 1 and S 2 ; S example is one of S 1 and S 3 ; S example is one of S 2 and S 3 ; S example is one of S 1 , S 2 and S 3 ; and S example is any equivalent of each one of these choices.
  • C i-j when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized.
  • the term C 1-3 refers independently to embodiments that have one carbon member (C 1 ), embodiments that have two carbon members (C 2 ), and embodiments that have three carbon members (C 3 ).
  • C n-m alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n ⁇ N ⁇ m, with m>n.
  • Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed.
  • reference to disubstituent -A-B-, where A ⁇ B, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.
  • R 1 is phenyl substituted with R a , where R a is —F, —I, —Cl, —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 or —NO 2
  • R 1 is substituted phenyl wherein R b is a —Br, —F, —C 1-4 alkyl, —OCH 3 , —OCH 2 CH 3 , —CF 3 , or —OCF 3 .
  • R 1 is phenyl substituted with R a , wherein R a is —F, —Cl, —CH 3 , —C(CH 3 ) 3 , —OCH 3 , or —OCH 2 CH 3 , and R b is —Br, —F, —C 1-4 alkyl, —OCH 3 , —OCH 2 CH 3 , —CF 3 , or —OCF 3 .
  • R 1 is substituted phenyl where R b is 2-thiophen-2-yl or 2-furan-2-yl.
  • R 1 is substituted phenyl where R b is phenyl, 3-chlorophenyl, 4-fluorophenyl, 3-fluorophenyl, 4-methylphenyl, or 4-trifluoromethylphenyl.
  • R 1 is substituted phenyl where R b is 1H-pyrrol-1-yl, 1H-pyrazol-1-yl, 1H-pyrazol-5-yl, 1H-imidazol-2-yl, 1-methyl-1H-imidazol-2-yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl, 2H-1,2,3-triazol-1-yl, 1H-1,2,4-triazol-5-yl, 2H-1,2,4-triazol-1-yl, 2H-1,2,4-triazol-3-yl, 4H-1,2,4-triazol-3-yl, 4H-1,2,4-triazol-4-yl, 1-methyl-1H-1,2,4-triazol-3-yl, 1-methyl-1H-1,2,4-triazol-5-yl or 1-(tetrahydro-2H-pyran-2-yl)-1H-pyra
  • R 1 is substituted phenyl, where R b is pyridin-2-yl, 3-chloropyridin-2-yl, 3-fluoropyridin-2-yl, 3-methylpyridin-2-yl, 4-methylpyridin-2-yl, 5-methylpyridin-2-yl, 6-methylpyridin-2-yl, 2-pyridin-3-yl, or 2-pyrimidin-2-yl.
  • R 1 is substituted phenyl, where R b is 3-methyl-1,2,4-oxadiazol-5-yl or oxazol-2-yl.
  • R 1 is phenyl substituted with R a , where R a is halo, —C 1-4 alkyl, or —C 1-4 alkoxy, and R b is triazole or pyrimidine substituted or unsubstituted with halo or —C 1-4 alkyl.
  • R 1 is (1-methylethyl)-2-(2H-1,2,3-triazol-2-yl)phenyl, 2-(1H-1,2,3-triazol-1-yl)phenyl, 2-(2H-1,2,3-triazol-2-yl)phenyl, 2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl, 2-methyl-6-(2H-1,2,3-triazol-2-yl)phenyl, 3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, 3-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl, 3-methoxy-2-(1H-1,2,3-triazol-1-yl)phenyl, 3-methoxy-2-(2H-1,2,3-triazol-1-yl)phenyl, 3-methoxy-2-(2H-1,2,3-triazol-1-yl)phenyl
  • R 1 is substituted pyridine, where R d is —CF 3 , —Br, or —OCH 2 CH 2 CH 3 .
  • R d is 1H-pyrazol-5-yl, 2H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl, 4H-1,2,3-triazol-1-yl, 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl, 3-methylpyridin-2-yl, or 3-methyl-1,2,4-oxadiazol-5-yl.
  • R d is 1H-pyrazol-5-yl, 2H-1,2,3-triazol-1-yl, or 2H-1,2,3-triazol-2-yl.
  • R 1 is 1-phenyl-1H-pyrazol-5-yl, 3-phenylthiophen-2-yl, 3-phenylfuran-2-yl, 5-phenyl-1,3-oxazol-4-yl, 5-phenylisoxazol-4-yl, 5-(2-fluorophenyl)-2-methyl-1,3-thiazol-4-yl, 2-methyl-5-phenyl-thiazol-4-yl, or 5-(4-fluorophenyl)-2-methyl-1,3-thiazol-4-yl.
  • R 1 is 3-methylfuran-2-yl, 9H-fluorene, quinoline, cinnoline; 3-(1H-pyrrol-1-yl)thiophen-2-yl, 8-[1,2,3]-triazol-2-yl-naphthalen-1-yl, 2,3-dihydro-1,4-benzodioxin-5-yl, 1H-indol-7-yl, 4-fluoronaphthalen-1-yl, and naphthalen-1-yl and R 2 is selected from the group consisting of 4,6-dimethylpyrimidin-2-yl, 4-phenyl-pyrimidin-2-yl, quinoxaline, or 4-methoxypyrimidin-2-yl.
  • R 2 is pyrimidine substituted with —F, —Cl, -D, —CD 3 , —CH 3 , ethyl, isopropyl, propyl, tert-butyl, —CF 3 , —OCH 3 , —N(CH 3 ) 2 , —CN, —OH, —CH 2 OH, —NO 2 , —CO 2 CH 3 , —CO 2 H, —C(O)N(CH 3 ) 2 , phenyl, furan-2-yl, thiophen-2-yl, 1H-pyrazol-4-yl, cyclopropyl, pyrrolidin-1-yl, or morpholin-4-yl.
  • R 2 is 4,6-dimethylpyrimidin-2-yl, 4,5-dimethylpyrimidin-2-yl, 4,6-dimethoxypyrimidin-2-yl, 4-phenyl-pyrimidin-2-yl, 4-furan-2-ylpyrimidin-2-yl, 4-methylpyrimidin-2-yl, 4-methoxypyrimidin-2-yl, 4-thiophen-2-ylpyrimidin-2-yl, N,N,6-trimethyl-pyrimidin-4-amine, 4-(trifluoromethyl)pyrimidin-2-yl, 4,5,6-trimethylpyrimidin-2-yl, 4-(trifluoromethyl)pyrimidine-5-carboxylate, 4-(trifluoromethyl)pyrimidine-5-carboxylic acid, 5-nitro-pyrimidin-2-yl, 6-methylpyrimidine-4-carboxylic acid, N,N-dimethyl-4-(triflouoromethyl)pyrimidine-5-carboxamide, N
  • R 2 is pyrimidine substituted with one or more —Cl, —F, —CH 3 , —CF 3 , —N(CH 3 ) 2 , -D, or —CD 3 .
  • R 2 is 4,6-dimethylpyrimidin-2-yl, 4,5-dimethylpyrimidin-2-yl, 4,6-dimethoxypyrimidin-2-yl, 4-methylpyrimidin-2-yl, 4-methoxypyrimidin-2-yl, N,N,6-trimethyl-pyrimidin-4-amine, 4-(trifluoromethyl)pyrimidin-2-yl, 4,5,6-trimethylpyrimidin-2-yl, 4,6-bis(trifluoromethyl)pyrimidin-2-yl, 6-methyl-pyrimidin-4-ol, 5-fluoro-4-methylpyrimidin-2-yl, 5-fluoropyrimidin-2-yl, 4-methoxy-6-methylpyrimidin-2-yl, 5-chloro-4-methylpyrimidin-2-yl, 5-chloro-4,6-dimethylpyrimidin-2-yl, 5-fluoro-4,6-dimethylpyrimidin-2-yl, 5-trifluoromethylpyrimiimidin-2-yl
  • R 2 is pyrazine or triazine substituted with one or more —CH 3 .
  • R 2 is pyridine substituted with one or more —F, —OCH 3 , —OCH 2 CH 3 , —CH 3 , or —CF 3 .
  • R 2 is benzooxazol-2-yl, 2-methylpyrimidin-4(3H)-one and 4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine and R 1 is phenyl, substituted in the ortho position with R b , where R b is 2H-1,2,3-triazol-2-yl, 2H-1,2,3-triazol-1-yl, 3-methyl-1,2,4-oxadiazol-5-yl or 2-pyrimidin-2-yl.
  • R 2 is quinoxalin-2-yl, 3-methylquinoxalin-2-yl, 6,7-difluoroquinoxalin-2-yl, 3-(trifluoromethyl)quinoxaline, 4-methylquinoline, or 6-fluoroquinazolin-2-yl and R 1 is phenyl substituted in the ortho position with R b , where R b is 2H-1,2,3-triazol-2-yl, 2H-1,2,3-triazol-1-yl, 3-methyl-1,2,4-oxadiazol-5-yl or 2-pyrimidin-2-yl.
  • R 3 is biphenyl or 2-methoxyphenyl and R 4 is (5-trifluoromethyl)-pyridin-2-yl, (5-trifluoromethyl)-pyrimidin-2-yl, 4,6-dimethylpyrimidin-2-yl, or quinoxalin-2-yl.
  • R 1 is 2-(1H-1,2,3-triazol-1-yl)phenyl, 2-(2H-1,2,3-triazol-2-yl)phenyl, 2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl, 2-methyl-6-(2H-1,2,3-triazol-2-yl)phenyl, 3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, 3-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl, 3-methoxy-2-(1H-1,2,3-triazol-1-yl)phenyl, 3-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl, 3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl, 3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl, 3-methyl-2-(2H
  • R 1 is 3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, 6-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, 4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl, or 3-[1,2,3]triazol-2-yl-pyridin-2-yl and R 2 is 4,6-dimethylpyrimidin-2-yl, 5-fluoro-4,6-dimethylpyrimidin-2-yl, or 5-fluoro-4-methylpyrimidin-2-yl.
  • a pharmaceutical composition therefore comprises an effective amount of at least one a compound of Formula (I) and Formula (II) or a pharmaceutically acceptable salt thereof.
  • the invention includes also pharmaceutically acceptable salts of the compounds of Formula (I) and Formula (II), preferably of those described above and of the specific compounds exemplified herein, and methods of treatment using such salts.
  • a “pharmaceutically acceptable salt” is intended to mean a salt of a free acid or base of a compound represented by Formula (I) and Formula (II), that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, G. S. Paulekuhn, et al., “Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database”, J. Med. Chem., 2007, 50:6665-72, S. M.
  • a compound of Formula (I) and Formula (II) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methyl benzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phen
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or
  • an inorganic acid such as hydrochloric acid, hydrobromic acid
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • suitable salts include organic salts derived from amino acids, such as N-methyl-D-glucamine, lysine, choline, glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • amino acids such as N-methyl-D-glucamine, lysine, choline, glycine and arginine
  • ammonia carbonates, bicarbonates, primary, secondary, and tertiary amines
  • cyclic amines such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine
  • inorganic salts derived
  • the invention also relates to pharmaceutically acceptable prodrugs of the compounds of Formula (I) and Formula (II), and treatment methods employing such pharmaceutically acceptable prodrugs.
  • prodrug means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I) or Formula (II)).
  • a “pharmaceutically acceptable prodrug” is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
  • Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of Formula (I) or Formula (II).
  • amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
  • amides include those derived from ammonia, primary C 1-6 alkyl amines and secondary di(C 1-6 alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties. Examples of amides include those that are derived from ammonia, C 1-3 alkyl primary amines, and di(C 1-2 alkyl)amines.
  • esters of the invention include C 1-7 alkyl, C 6-7 cycloalkyl, phenyl, and phenyl(C 1-6 alkyl) esters.
  • Preferred esters include methyl esters.
  • Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Fleisher et al., Adv. Drug Delivery Rev. 1996, 19, 115-130. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs.
  • Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs.
  • Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs.
  • Prodrugs of this type may be prepared as described in Robinson et al., J Med Chem. 1996, 39(I), 10-18.
  • Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.
  • the present invention also relates to pharmaceutically active metabolites of the compounds of Formula (I) or Formula (II), which may also be used in the methods of the invention.
  • a “pharmaceutically active metabolite” means a pharmacologically active product of metabolism in the body of a compound of Formula (I) or Formula (II) or salt thereof.
  • Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini, et al., J Med Chem. 1997, 40, 2011-2016; Shan, et al., J Pharm Sci. 1997, 86 (7), 765-767; Bagshawe, Drug Dev Res. 1995, 34, 220-230; Bodor, Adv Drug Res.
  • the compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of the present invention are useful as modulators of the orexin receptor in the methods of the invention.
  • the compounds may act as antagonists, agonists, or inverse agonists.
  • modulators include both inhibitors and activators, where “inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize or down-regulate orexin receptor expression or activity, and “activators” are compounds that increase, activate, facilitate, sensitize, or up-regulate orexin receptor expression or activity.
  • treat or “treating” as used herein is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of orexin receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of orexin receptor activity.
  • subject refers to a mammalian patient in need of such treatment, such as a human.
  • the invention relates to methods of using the compounds described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated by orexin receptor activity, such as: disorders of the sleep-wake cycle, metabolic disorders, neurological disorders and other disorders (e.g., feeding, drinking, arousal, stress, addiction, metabolism and reproduction). Symptoms or disease states are intended to be included within the scope of “medical conditions, disorders, or diseases.”
  • Sleep disorders include, but are not limited to, sleep-wake transition disorders, insomnia, restless legs syndrome, jet-lag, disturbed sleep, and sleep disorders secondary to neurological disorders (e.g., manias, depressions, manic depression, schizophrenia, and pain syndromes (e.g., fibromyalgia, neuropathic).
  • neurological disorders e.g., manias, depressions, manic depression, schizophrenia, and pain syndromes (e.g., fibromyalgia, neuropathic).
  • Metabolic disorders include, but are not limited to, overweight or obesity and conditions related to overweight or obesity, such as insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins and osteoarthritis.
  • Neurological disorders include, but are not limited to, Parkinson's disease, Alzheimer's disease, Tourette's Syndrome, catatonia, anxiety, delirium and dementias.
  • disorders include, but are not limited to, ulcers, irritable bowel syndrome, diarrhea and gastroesophageal reflux.
  • an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition.
  • An “effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition.
  • Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
  • An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID).
  • a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
  • the dose may be adjusted for preventative or maintenance treatment.
  • the dosage or the frequency of administration, or both may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained.
  • treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
  • the active agents of the invention may be used in combination with additional active ingredients in the treatment of the above conditions.
  • the additional active ingredients may be coadministered separately with an active agent of compounds of Formulas (I) and (II) or included with such an agent in a pharmaceutical composition according to the invention.
  • additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by orexin activity, such as another orexin modulator or a compound active against another target associated with the particular condition, disorder, or disease.
  • the combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.
  • a pharmaceutical composition of the invention comprises: (a) an effective amount of at least one active agent in accordance with the invention; and (b) a pharmaceutically acceptable excipient.
  • a “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a agent and that is compatible therewith.
  • excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
  • compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art.
  • the compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
  • the preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories.
  • the compositions are formulated for intravenous infusion, topical administration, or oral administration.
  • the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension.
  • the compounds may be formulated to yield a dosage of, e.g., from about 0.05 to about 100 mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily.
  • a total daily dosage of about 5 mg to 5 g daily may be accomplished by dosing once, twice, three, or four times per day.
  • Oral tablets may include a compound according to the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
  • suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
  • Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
  • Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents.
  • Binding agents may include starch and gelatin.
  • the lubricating agent if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
  • Capsules for oral administration include hard and soft gelatin capsules.
  • compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent.
  • Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
  • Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
  • suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose,
  • the active agents of this invention may also be administered by non-oral routes.
  • the compositions may be formulated for rectal administration as a suppository.
  • parenteral use including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the compounds of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
  • Illustrative infusion doses may range from about 1 to 1000 ⁇ g/kg/minute of compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
  • the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
  • a pharmaceutical carrier for topical administration, may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
  • Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery.
  • Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
  • HET is a 5-6 membered heteroaryl ring containing one to three nitrogen members, in the presence of copper(I)iodide, Cs 2 CO 3 and N,N′-dimethylcyclohexane-1,2-diamine; in a solvent such as DMF or dioxane, at temperatures ranging from 60° C. to 100° C. (using conventional or microwave heating).
  • 1,2,3-triazole can exist in two tautomeric forms defined as 2H-[1,2,3]triazole and 1H-[1,2,3]triazole thus accounting for the formation of two regioisomers.
  • compounds of formula (VIb) are prepared by the reaction of halobenzonitrile compounds of formula (VII) with HET, where HET is a 5-membered heteroaryl ring selected from the group consisting of triazole or pyrazole, in a solvent such as DMF and the like, in the presence of an inorganic base such as K 2 CO 3 and the like, at temperatures ranging from 100° C. to 130° C. Subsequent hydrolysis of the nitrile using a base such as aqueous NaOH and the like, in a solvent such as methanol provides compounds of formula (VIb).
  • Compounds of formula (VIb) are also prepared by the reaction of halobenzonitrile compounds of formula (VII) with HET-Sn(alkyl) 3 , where HET-Sn(alkyl) 3 is a commercially available or synthetically accessible trialkyltinheteroaryl compound, in a solvent such as DME, in the presence of a palladium catalyst such as Pd(PPh 3 ) 4 , in the presence or absence of a catalytic amount of copper iodide, at temperatures ranging from 100° C. to 160° C., using conventional or microwave heating. Subsequent hydrolysis of the nitrile using a base such as aqueous NaOH and the like, in a solvent such as methanol provides compounds of formula (VIb).
  • Compounds of formula (VIb) are also prepared by the reaction of halobenzonitrile compounds of formula (VII) with HET-boronic acid, where HET-boronic acid is a commercially available or synthetically accessible heteroarylboronic acid, in a solvent such as DME, in the presence of a base such as NaHCO 3 , a palladium catalyst such as Pd(PPh 3 ) 4 , at temperatures ranging from 80° C. to the reflux temperature of the solvent. Subsequent hydrolysis using a base such as aqueous NaOH and the like, in a solvent such as methanol provides compounds of formula (VIb).
  • compounds of formula (VIc) are obtained from compounds of formula (IV), by first converting a commercially available or synthetically accessible compound of formula (IV), where R a2 is —H, halo, —C 1-4 alkyl, —C 1-4 alkoxy, —CF 3 , or —NO 2 , and where X is C or N (with the proviso that only one X may be N) to one of formula (IX) under esterification conditions, for example by treating an alcohol solution of a compound of formula (IV) with an acid.
  • the compound of formula (IV) is dissolved in a solvent such as MeOH and treated with H 2 SO 4 to afford a compound of formula (IX).
  • a compound of formula (X) is obtained by reacting a suitable compound of formula (IX) with pinacol borane in the presence of a phosphine and a palladium catalyst, in the presence of an amine base, in a solvent such as THF, at temperatures ranging from room temperature to 70° C.
  • the phosphine is tri(o-tolyl)phosphine
  • the palladium catalyst is Pd(OAc) 2
  • the amine base is triethylamine.
  • a compound of formula (VIc) is obtained by reacting a compound of formula (X) with a compound R b2 —Cl, where R b2 —Cl is a suitable commercially available or synthetically accessible 6-membered chloro-substituted heteroaryl compound, in the presence of a palladium catalyst, a base such as Na 2 CO 3 , and the like, in a solvent such as 2-methyl-tetrahydrofuran (2-methyl-THF), and the like, at temperatures ranging from room temperature to 80° C.
  • the palladium catalyst is PdCl 2 (dppf)-dcm adduct
  • the base is Na 2 CO 3
  • the solvent is 2-methyl-THF.
  • a compound of formula (VIc) is obtained from a compound of formula (XI) via ester hydrolysis.
  • a compound of formula (XI) in methyl-THF is treated with aqueous NaOH to afford a compound of formula (VIc).
  • substituted heteroaryl compounds R 2 Cl of formula (XIVa) and (XVIb) are prepared from commercially available or synthetically accessible compounds of formula (XIIIa) or (XIIIb).
  • Pyrimidols of formula (XIIIa) or formula (XIIIb) are commercially available or are prepared by reacting substituted alkyl malonates of formula (XII), where R e is halo, with urea in the presence of a base such as sodium ethoxide and the like; in a suitable solvent such as ethanol, at temperatures between room temperature and the reflux temperature of the solvent.
  • a chlorinating agent such as oxalyl chloride and the like
  • a solvent such as CH 2 Cl 2
  • a base such as N,N-dimethylaniline and the like
  • Chloropyrimidines of formula (XIVa) or (XIVb) are reacted with Grignard reagents (R g MgBr) of formula (XV); in the presence of a catalytic amount of Fe(acac) 3 , in a solvent such as Et 2 O at 0° C., provides alkyl chloropyrimidines of formula (XVIa) or (XVIb).
  • compounds of formula (XX) are obtained from synthetically accessible or commercially available 2-benzyl-octahydro-pyrrolo[3,4-c]pyrrole by first protecting the secondary nitrogen of 2-benzyl-octahydro-pyrrolo[3,4-c]pyrrole as a carbamate.
  • the carbamate is the tert-butylcarbamate (boc) which is introduced by treating 2-benzyl-octahydro-pyrrolo[3,4-c]pyrrole with di-tert-butyl-dicarbonate, in a solvent such as DCM, affording compound (XVII).
  • Compound (XVIII) is obtained from treating compound (XVII) with hydrogen gas, in the presence of a catalyst.
  • the catalyst is Pd on carbon, in a solvent such as MeOH in the presence of AcOH.
  • a compound of formula (XIX) is obtained by treating compound (XVIII) with a compound of formula R 2 Cl, where R 2 is as defined in formula (I).
  • tertiary organic or inorganic base such as Cs 2 CO 3 , Na 2 CO 3 , TEA, and the like
  • a solvent such as DMF, dichloromethane, THF, n-butanol, and the like; at a temperature between room temperature and the reflux temperature of the solvent, using conventional or microwave heating, to afford compounds of formula (XIX).
  • the base is Cs 2 CO 3 and the solvent is DMF.
  • tert-butylcarbamate (boc) in compounds of formula (XIX) is accomplished by using methods known to one skilled in the art, such as, HCl, TFA, or p-toluenesulfonic acid, in a solvent such as CH 3 OH, dioxane, or CH 2 Cl 2 .
  • a compound of formula (XIX) is treated with TFA in DCM or HCl to afford a compound of formula (XX).
  • a tertiary organic or inorganic base such as Cs 2 CO 3 , Na 2 CO 3 , TEA, and the like; in a solvent such as DMF, dichloromethane, THF, and the like; at a temperature between room temperature and the reflux temperature of the solvent to afford a compound of formula (XXI).
  • the base is Cs 2 CO 3 and the solvent is DMF.
  • a compound of formula (XX) is obtained by treating a compound of formula (XXI) with hydrogen gas, in the presence of a catalyst, in a solvent such as AcOH.
  • the catalyst is Pd on carbon.
  • a compound of formula (I) is obtained from a compound of formula (XIX), (XX), or (XXI) by reacting a compound of formula (XIX), (XX), or (XXI) with a compound of formula R 1 CO 2 H under amide formation conditions.
  • Compounds of formula R 1 CO 2 H, where R 1 is as defined in formula (I) are commercially available, as described, or synthetically accessible appropriately substituted aryl or heteroaryl carboxylic acids.
  • a compound of formula (XIX), (XX), or (XXI), either as a free base or as an acid salt is reacted with a compound of formula R 1 CO 2 H, in the presence of a dehydrating agent such as HOBt/EDAC, CU, HATU, HOAT; a suitably selected base such as DIPEA, TEA, and the like; in an organic solvent or mixture thereof, such as toluene, acetonitrile, ethyl acetate, DMF, THF, methylene chloride, and the like; to afford a compound of formula (XXII), (XXIII) or (I).
  • the dehydrating agent is HATU
  • the base is DIPEA.
  • a compound of formula R 1 CO 2 H (as described above) may be first converted to a compound of formula R 1 COCl, or compound of formula R 1 COCl is a commercially available substituted aryl sulfonyl chloride.
  • a compound of formula R 1 CO 2 H is treated with thionyl chloride in a solvent such as toluene to afford a compound of formula R 1 COCl.
  • a compound of formula (I) is obtained by treating a compound of formula R 1 COCl with a compound of formula (XIX), (XX), or (XXI), a suitably selected tertiary organic base such as TEA, and the like, in a solvent such as dichloromethane, THF, and the like, at a temperature between room temperature and the reflux temperature of the solvent.
  • a compound of formula (II) is obtained by treating a compound of formula R 1 SO 2 Cl with a compound of formula (XIX), (XXI), or (XXV), where R 4 is (5-trifluoromethyl)-pyridin-2-yl, (5-trifluoromethyl)-pyrimidin-2-yl, 4,6-dimethylpyrimidin-2-yl, or quinoxalin-2-yl; a suitably selected tertiary organic base such as TEA, and the like, in a solvent such as dichloromethane, THF, and the like, at a temperature between room temperature and the reflux temperature of the solvent.
  • a compound of formula (XIX), (XXI), or (XXV) where R 4 is (5-trifluoromethyl)-pyridin-2-yl, (5-trifluoromethyl)-pyrimidin-2-yl, 4,6-dimethylpyrimidin-2-yl, or quinoxalin-2-yl; a suitably selected ter
  • 3-Fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid and 2-fluoro-6-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid are prepared according to SCHEME H.
  • 3-Fluorophthalic anhydride was dissolved in a solvent such as MeOH, at temperatures ranging from room temperature to the reflux temperature of the solvent, to provide acid-esters (XXVIIa) and (XXIIb).
  • Conversion of the acid to the acid chloride is accomplished under standard chlorination conditions.
  • the acid is heated with oxalyl chloride in a solvent such as DCM.
  • esters (XXVIIIa) and (XXVIIIb) are converted to a mixture of esters (XXIXa) and (XXIXb) and acids (XXXa) and (XXXb) by treatment with a base, preferably sodium acetate, in the presence of a solvent, preferably t-BuOH.
  • acid (XXXa) is prepared by first converting 2-fluoro-6-iodobenzoic acid to the acid chloride by reaction with a chlorinating agent such as oxalyl chloride, in a solvent such as DCM, with a catalytic amount of DMF, at a temperature of 0° C. Subsequent reaction of the acid chloride with N-hydroxyacetamide in a solvent such as CH 2 Cl 2 provides (Z)—N′-((2-fluoro-6-iodobenzoyl)oxy)acetimidamide.
  • 5-(2-Fluoro-6-iodophenyl)-3-methyl-1,2,4-oxadiazole is prepared by reacting (Z)—N′-((2-fluoro-6-iodobenzoyl)oxy)acetimidamide with sodium acetate, in a solvent such as tert-butanol, at temperatures ranging from 100° C. to 110° C.
  • 3-Fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid is prepared by reacting 5-(2-fluoro-6-iodophenyl)-3-methyl-1,2,4-oxadiazole with a grignard reagent such as i-PrMgCl, in a suitable solvent such as THF and the like, at a temperature of ⁇ 78° C. Subsequent addition of CO 2 gas, at a temperature of ⁇ 78° C. provides 3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (XXXa).
  • Deuterated pyrimidine compounds of formula (XXXII) are prepared according to Scheme H. Acetylacetone is reacted with an inorganic base such as K 2 CO 3 in deuterated water, at temperatures ranging from 100° C. to 120° C. to provide 1,1,1,3,3,3,5,5-octadeuteriopentane-2,4-dione. 1,1,1,3,3,3,5,5-Octadeuteriopentane-2,4-dione is subsequently reacted with deuterated urea, in a solvent such as deuterated ethanol, 35% wt. DCl in D 2 O, at temperatures ranging from 90° C. to 100° C. to provide deuterated pyrimidinols of formula (XXXI). Chlorination under standard chlorinating conditions provides chlorodetuteratedpyrimidine compounds of formula (XXXII).
  • amines of formula (I) may be converted to their corresponding salts using methods known to those skilled in the art.
  • amines of formula (I) may be treated with trifluoroacetic acid (TFA), HCl, maleic acid, or citric acid in a solvent such as diethyl ether (Et 2 O), CH 2 Cl 2 , tetrahydrofuran (THF), or methanol (MeOH) to provide the corresponding salt forms.
  • THF diethyl ether
  • MeOH methanol
  • the acid is HCl and the solvent is isopropanol.
  • Compounds prepared according to the schemes described above may be obtained as single enantiomers, diastereomers, or regioisomers, by enantio-, diastero-, or regiospecific synthesis, or by resolution.
  • Compounds prepared according to the schemes above may alternately be obtained as racemic (1:1) or non-racemic (not 1:1) mixtures or as mixtures of diastereomers or regioisomers.
  • single enantiomers may be isolated using conventional separation methods known to one skilled in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation.
  • separation methods known to one skilled in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation.
  • regioisomeric or diastereomeric mixtures are obtained, single isomers may be separated using conventional methods such as chromatography or crystallization.
  • reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were “dried,” they were generally dried over a drying agent such as Na 2 SO 4 or MgSO 4 . Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM Discover instrument.
  • Normal-phase flash column chromatography was performed on silica gel (SiO 2 ) using prepackaged cartridges, eluting with the indicated solvents.
  • Preparative reverse-phase high performance liquid chromatography HPLC was performed on a Gilson HPLC with an Xterra Prep RP 18 or an XBridge C18 OBD (5 ⁇ m, 30 ⁇ 100 mm, or 50 ⁇ 150 mm) column, and a gradient of 10 to 99% acetonitrile/water (20 mM NH 4 OH) over 12 to 18 min, and a flow rate of 30 mL/min.
  • Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.
  • Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. The format of the 1 H NMR data below is: chemical shift in ppm downfield of the tetramethylsilane reference (multiplicity, coupling constant J in Hz, integration).
  • 5-Fluoro-2-[1,2,3]triazol-2-yl-benzoic acid To a solution of 5-fluoro-2-iodo-benzoic acid (3.86 g, 14.65 mmol), 2H-[1,2,3]triazole (2.5 g, 36.2 mmol), Cs 2 CO 3 (8.62 g, 24.5 mmol), trans-N,N′-dimethyl-cyclohexane-1,2-diamine (0.4 mL), CuI (244 mg) and DMF (13 mL) were added to a microwave ready vessel and heated to 100° C. for 10 min. The mixture was cooled, diluted with water, and extracted with EtOAc.
  • Method A The title compound was prepared in a manner analogous to Intermediate 1, substituting 2-fluoro-6-iodo-benzoic acid for 5-fluoro-2-iodo-benzoic acid.
  • Method B 2-Fluoro-6-[1,2,3]triazol-2-yl-benzoic acid.
  • 2-fluoro-6-iodobenzoic acid 127.6 g, 480 mmol
  • copper iodide 4.57 g, 24 mmol
  • Cs 2 CO 3 312.6 g, 959 mmol
  • Step A 5-Fluoro-2-iodo-benzoic acid methyl ester.
  • 5-fluoro-2-iodo-benzoic acid 23 g, 86.5 mmol
  • methanol 230 mL
  • conc. sulfuric acid 2.3 mL, 43.2 mmol
  • the reaction mixture was warmed to 65° C. and stirred for 15 h.
  • the resulting mixture was concentrated under reduced pressure to give crude product which was then was partitioned between EtOAc (250 mL) and a half sat. Na 2 CO 3(aq) solution (250 mL). The layers were thoroughly mixed and then separated.
  • Step B 5-Fluoro-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester.
  • 5-fluoro-2-iodo-benzoic acid methyl ester 23 g, 82 mmol
  • Anhydrous triethylamine 34 mL, 246.4 mmol
  • Pinacol borane (17.9 mL, 123.2 mmol) was added and the reaction mixture was degassed once more for 5 minutes. Lastly, tri(o-tolyl)phosphine (1.25 g, 4.1 mmol) and palladium acetate (461 mg, 2.053 mmol) were added. Again, the reaction mixture was degassed with a nitrogen sparge. The mixture was heated to 65° C. and stirred for 1 h. After cooling to room temperature, the reaction mixture was quenched with half sat. ammonium chloride solution (250 mL), and the resulting layers were separated.
  • the aqueous layer was extracted with additional ethyl acetate (250 mL) and the combined organics were dried over magnesium sulfate. After filtration and concentration, the crude product was obtained as a yellow oil (23 g). The crude product was then slurried in 25% EtOAc/hexanes (250 mL). The resulting solids were not desired product and were removed by filtration. The resulting solution was then concentrated to a yellow oil (21 g, 75 wt % desired, 16.1 g actual product, 70% yield), which was used directly in the next step.
  • Step C 5-Fluoro-2-pyrimidin-2-yl-benzoic acid methyl ester.
  • 5-fluoro-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester 5.9 g, 21.06 mmol
  • 2-methyl-THF 50 mL
  • 2-chloropyrimidine 2.9 g, 25.28 mmol
  • sodium carbonate 6. g, 63.19 mmol
  • water 17.17 mL
  • PdCl 2 (dppf)-dcm adduct (CAS#72287-26-4) (0.688 g, 0.843 mmol) was added and the reaction mixture was degassed once more for 30 minutes. The reaction mixture was warmed to 74° C. and stirred overnight. To the resulting solution was added diethyl ether (100 mL) and water (100 mL). The layers were thoroughly mixed then separated. The aqueous layer was extracted with additional diethyl ether (100 mL). The combined organics were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to a brown crude material (5.85 g, 49% desired, 2.87 actual product).
  • Step D 5-Fluoro-2-pyrimidin-2-yl-benzoic acid.
  • 5-fluoro-2-pyrimidin-2-ylbenzoic acid methyl ester (1.72 g, 7.407 mmol) in 2-methyl-THF (20 mL) was added sodium hydroxide (0.74 g, 18.517 mmol) and water (20 mL). The mixture was heated to 72° C. and stirred for 2 h. The layers were separated and the aqueous layer was extracted with additional MTBE. A 50% HCl (aq) solution was then dripped into the aqueous layer until a pH of 1 was reached.
  • Step A 2-Fluoro-6-iodo-benzoic acid methyl ester.
  • 2-fluoro-6-iodo-benzoic acid 7.5 g, 28.2 mmol
  • LiOH.H 2 O 1.42 g, 33.8 mmol
  • THF 100 mL
  • Dimethyl sulfate 4.03 mL, 42.3 mmol
  • the mixture was warmed to 65° C.
  • the mixture was cooled to room temperature and NH 4 Cl (aq) (50 mL, 13 wt % solution) was added.
  • Step B 2-Fluoro-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester.
  • 2-fluoro-6-iodo-benzoic acid methyl ester 7.29, 26.0 mmol
  • anhydrous THF 150 mL
  • This mixture was cooled to 0° C. and i-PrMgCl (13.7 mL, 2 M in THF, 27.3 mmol) was added dropwise.
  • Step C 2-Fluoro-6-pyrimidin-2-yl-benzoic acid methyl ester.
  • 2-fluoro-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester 5.46 g, 19.5 mmol
  • 2-methyl-THF 50 mL
  • 2-chloropyrimidine 2.68 g, 23.4 mmol
  • sodium carbonate 6.2 g, 58.5 mmol
  • PdCl 2 (dppf)-dcm adduct (CAS#72287-26-4) (1.27 g, 1.56 mmol) was then added and the reaction mixture was warmed to 74° C. and stirred for 2.5 h. After cooling, the mixture was diluted with MTBE (50 mL) and water (80 mL). The layers were thoroughly mixed then separated. The aqueous layer was extracted with additional MTBE (100 mL). The combined organics were dried over magnesium sulfate, filtered, concentrated and then purified by flash chromatography (0-25% EA/hexanes) to provide the title compound (1.72 g, 72 wt %, 30% yield).
  • Step D 2-Fluoro-6-pyrimidin-2-yl-benzoic acid.
  • 2-fluoro-6-pyrimidin-2-yl-benzoic acid methyl ester (1.36 g, 5.85 mmol) in 2-methyl-THF (20 mL) was added sodium hydroxide (2 M in water, 9.3 mL, 18.6 mmol).
  • the mixture was heated to 72° C. and stirred for 9 h.
  • the layers were separated and the aqueous layer acified to pH 2 by dropwise addition of 50% HCl (aq) (3.1 mL).
  • Step A 5-Benzyl-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester.
  • 2-benzyl-octahydro-pyrrolo[3,4-c]pyrrole 5.62 g, 27.8 mmol
  • DCM 100 mL
  • Boc 2-benzyl-octahydro-pyrrolo[3,4-c]pyrrole
  • the reaction mixture was stirred for 24 hours at 23° C.
  • the solvent was removed in vacuo and the resulting product was used in the next step without further purification.
  • MS (ESI) mass mass calcd.
  • Step B Hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester.
  • 5-Benzyl-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester (19.85 g, 65.6 mmol), MeOH (200 mL), HOAc (3 mL) and 10% Pd/C Degussa type (400 mg) were charged to a Parr shaker vial and shaken for 3 days at 70 psi hydrogen gas. The resulting material was filtered through Celite® and concentrated.
  • Step A 5-(2-Fluoro-6-[1,2,3]triazol-2-yl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester.
  • toluene 8.5 mL
  • aqueous sodium carbonate 1.42 g in 10.7 mL water
  • Intermediate 15 0.05 mg, 4.26 mmol
  • Step B (2-Fluoro-6-[1,2,3]triazol-2-yl-phenyl)-(hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-methanone.
  • 5-(2-Fluoro-6-[1,2,3]triazol-2-yl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester (1.3 g, 3.21 mmol) was taken up in DCM (6.0 mL) and TFA (3.0 mL) was added. The mixture was allowed to stir at rt for 1 hr.
  • Step A 2-Fluoro-6-[1,2,3]triazol-2-yl-benzoic acid (0.97 g, 4.71 mmol), hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester (Intermediate 15, 1.0 g, 4.71 mmol), HATU (2.68 g, 7.06 mmol), in DMF (18.8 mL) was added DIEA (2.43 mL, 14.13 mmol). The mixture was stirred at rt for 1 hr. The mixture was diluted with EtOAc and washed with water.
  • Step B (2-Fluoro-6-[1,2,3]triazol-2-yl-phenyl)-(hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-methanone.
  • the title compound was prepared in a manner analogous to Intermediate 16, Method A, Step B.
  • Step A 5-(4,6-Dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester.
  • Hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester (1.20 g, 5.6 mmol)
  • 2-chloro-4,6-dimethyl-pyrimidine (1.03 g, 7.2 mmol)
  • Cs 2 CO 3 (2.12 g, 6.5 mmol
  • DMF 15 mL
  • Step B 2-(4,6-Dimethyl-pyrimidin-2-yl)-octahydro-pyrrolo[3,4-c]pyrrole.
  • DCM (10 mL) and TFA (5 mL) were stirred at 23° C. for 2 h. The mixture was concentrated to remove the volatiles, diluted with EtOAc and 1N aq. NaOH, and extracted with EtOAc (3 ⁇ ).
  • Step A 2-Benzyl-5-(4,6-dimethyl-pyrimidin-2-yl)-octahydro-pyrrolo[3,4-c]pyrrole.
  • 2-benzyl-octahydro-pyrrolo[3,4-c]pyrrole 109 g, 538.8 mmol
  • DMF 1,3-bis(trimethoxy)-2-butane
  • 2-chloro-4,6-methylpyrimidine 76.8 g, 538.8 mmol
  • Cs 2 CO 3 351.1 g, 1.08 mol
  • Step B 2-(4,6-Dimethyl-pyrimidin-2-yl)-octahydro-pyrrolo[3,4-c]pyrrole.HOAc.
  • 5% Pd/C 66.9 g, Johnson Matthey 5R338, 56.8% H 2 O, 3.45 mol %
  • 2-benzyl-5-(4,6-dimethyl-pyrimidin-2-yl)-octahydro-pyrrolo[3,4-c]pyrrole 160 g, 519 mmol
  • acetic acid (30 mL, 519 mmol) in ethanol (3.2 L).
  • Step A Intermediate 24 was prepared in a manner analogous to Intermediate 23, Method A, substituting (4-chloro-6-methoxy-pyrimidin-2-yl)-dimethyl-amine for 2-chloro-4,6-dimethyl-pyrimidine in Step A to afford 5-(2-dimethylamino-6-methoxy-pyrimidin-4-yl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester.
  • Step B [4-(Hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-6-methoxy-pyrimidin-2-yl]-dimethyl-amine.
  • Step A The title compound was prepared in a manner analogous to Intermediate 23, Method A, substituting (6-chloro-2-trifluoromethyl-pyrimidin-4-yl)-dimethyl-amine for 2-chloro-4,6-dimethyl-pyrimidine in Step A to afford 5-(6-dimethylamino-2-trifluoromethyl-pyrimidin-4-yl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester.
  • Step B [6-(Hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-2-trifluoromethyl-pyrimidin-4-yl]-dimethyl-amine.
  • Step A 3-Fluoro-2-(pyrimidin-2-yl)benzonitrile.
  • 2-Iodo-3-fluorobenzonitrile (2.5 g, 10.3 mmol) and 2-tributylstannane pyrimidine (3.7 g, 10.0 mmol) were combined and dissolved in degassed DME (18 ml) then purged with bubbling N 2 for 5 minutes.
  • the reaction was treated with Pd(PPh 3 ) 4 (577 mg, 0.5 mmol) and then purged with bubbling for 5 minutes in a sealed vessel and then heated in microwave at 160° C. for 90 min.
  • Step B 3-Fluoro-2-(pyrimidin-2-yl)benzoic acid.
  • Step A Methyl 2-bromo-5-fluorobenzoate (1.0 g, 4.2 mmol) and (1H-pyrazol-5-yl)boronic acid (485 mg, 4.6 mmol) were combined and dissolved in degassed DME (15 ml) then treated with NaHCO 3 (706 mg, 8.4 mmol) in water and the reaction purged with bubbling N 2 for 5 minutes. The reaction was treated with Pd(PPh 3 ) 4 (243 mg (0.2 mmol) and then purged with bubbling for 5 minutes in a sealed vessel and then heated to reflux for 2 h. The reaction mixture was cooled to 23° C., filtered, and solid rinsed with EtOAc. The organic layers were separated, dried and concentrated. Purification via FCC (ethyl acatate/hexanes, 0-30%) afforded methyl 5-fluoro-2-(1H-pyrazol-5-yl)benzoate (415 mg, 44%).
  • FCC ethyl a
  • Step A 3-Fluoro-2-(2H-1,2,3-triazol-2-yl)benzonitrile and 3-fluoro-2-(1H-1,2,3-triazol-1-yl)benzonitrile.
  • a mixture of 2,3-difluorobenzonitrile (4.0 g, 28.8 mmol), 2H-1,2,3-triazole (1.9 g, 28.8 mmol) in DMF (85.0 mL) and K 2 CO 3 (7.9 g, 57.5 mmol) were heated to 125° C. for 1.5 h. After cooling to rt, water was added and the mixture extracted with EtOAc (2 ⁇ ). The combined organics were washed with brine and dried (Na 2 SO 4 ).
  • Step B 3-Fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid.
  • MeOH MeOH
  • 2M aq. NaOH 10 mL
  • the combined organics were washed with brine and dried (Na 2 SO 4 ). Purification via Agilent (Reverse-Phase HPLC, basic conditions) gave the title compound (290 mg, 18%).
  • Step A 2-Fluoro-6-(methoxycarbonyl)benzoic acid.
  • 3-Fluorophthalic anhydride (377 mg, 2.27 mmol) was dissolved in MeOH (6 mL) and heated to reflux for 15 h. The mixture was concentrated in vacuo and the two products (400 mg, 89%), 2-fluoro-6-(methoxycarbonyl)benzoic acid and 3-fluoro-2-(methoxycarbonyl)benzoic acid, were taken on to the next step without purification.
  • Step B (Z)-Methyl 2-((((1-aminoethylidene)amino)oxy)carbonyl)-3-fluorobenzoate.
  • oxalyl chloride 0.244 mL, 2.32 mmol
  • DMF 0.05 mL
  • the viscous liquid was dissolved in fresh DCM (5 mL) and treated with solid N-hydroxyacetamidine (165 mg, 2.22 mmol) in several portions followed by TEA (0.351 mL, 2.52 mmol). After stirring for 14 h at ambient temperature the mixture was concentrated in vacuo.
  • Step C 3-Fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid.
  • t-BuOH 9 mL
  • NaOAc 156 mg, 1.88 mmol
  • the mixture was heated at 90° C. for 50 h and then concentrated in vacuo. This resulted in four products. The residue was dissolved in 1M aq.
  • the acid isomers were purified on a Prep Agilent system with a XBridge C 18 OBD 50 ⁇ 100 mm column eluting with 5 to 99% 0.05% NH 4 OH in H 2 O/ACN over 17 min to afford the desired product (63 mg, 15%) as a white solid after acidification with 1M aq. HCl in Et 2 O.
  • Step A (Z)—N′-((2-Fluoro-6-iodobenzoyl)oxy)acetimidamide.
  • 2-fluoro-6-iodobenzoic acid (1.51 g, 5.66 mmol) at 0° C. in DCM (28 mL) was added oxalyl chloride (0.635 mL, 7.36 mmol) followed by DMF (0.15 mL).
  • oxalyl chloride 0.635 mL, 7.36 mmol
  • DMF 0.15 mL
  • Step B 5-(2-Fluoro-6-iodophenyl)-3-methyl-1,2,4-oxadiazole.
  • NaOAc 603 mg, 7.27 mmol
  • H 2 O 0.9 mL
  • the reaction was concentrated in vacuo and then dissolved in toluene.
  • the toluene was then filtered to remove NaOAc and then concentrated in vacuo. Chromatography (Hex to 40% EtOAc/Hex) afforded the desired product as a colorless oil (1.21 g, 82%).
  • Step C 3-Fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid.
  • THF 15 mL
  • 2 M i-PrMgCl in THF 2.2 mL, 4.47 mmol
  • This mixture was cooled to ⁇ 78° C. and the product of Step B (1.09 g, 3.58 mmol) was added dropwise in THF (20 mL).
  • the mixture was stirred for 30 min at ⁇ 78° C. and then CO 2 from a lecture bottle was bubbled into the solution for 3 h while allowing the temperature to slowly rise. When the temperature reached ⁇ 20° C.
  • Step A tert-Butyl 5-(3-(2H-1,2,3-triazol-2-yl)picolinoyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate.
  • tert-Butyl 5-(3-(2H-1,2,3-triazol-2-yl)picolinoyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate was prepared in a manner analogous to Intermediate 59 substituting 3-[1,2,3]triazol-2-yl-pyridine-2-carboxylic acid (Intermediate 72) for 2-(4H-[1,2,4]triazol-3-yl)benzoic acid.
  • Step B (3-(2H-1,2,3-Triazol-2-yl)pyridin-2-yl)(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methanone.
  • tert-Butyl 5-(3-(2H-1,2,3-triazol-2-yl)picolinoyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (491 mg, 1.28 mmol) in DCM (6 mL) was added TFA (3 mL). After stirring for 2 h at room temperature the reaction was complete and concentrated in vacuo.
  • the TFA salt was purified on a Prep Agilent system with a XBridge C 18 OBD 50 ⁇ 100 mm column eluting with 5 to 99% 0.05% NH 4 OH in H 2 O/ACN over 17 min to afford (3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methanone as a white solid (306 mg, 84%).
  • Step A 5-Fluoropyrimidine-2,4,6-triol.
  • urea 641 mg, 10.67 mmol
  • diethylfluoromalonate (1.96 g, 10.67 mmol)
  • EtOH 11 mL
  • 2.68 M NaOEt in EtOH 7.96 mL, 21.34 mmol
  • the mixture was heated at reflux for 60 h and then allowed to cool to room temperature.
  • the mixture was filtered and the cake was then dissolved in warm water and the resulting solution was acidified with concentrated HCl to pH 2.
  • the mixture was allowed to cool to room temperature and then cooled in an ice bath before filtering.
  • the cake was washed with water and dried to afford 5-fluoropyrimidine-2,4,6-triol as a slightly off white solid (1.45 g, 93%).
  • Step B 2,4,6-Trichloro-5-fluoropyrimidine.
  • POCl 3 (4.49 mL, 48.15 mmol) was added 5-fluoropyrimidine-2,4,6-triol (1.41 g, 9.63 mmol) in several portions. There was a 2° C. increase in temperature.
  • the N,N-dimethylaniline (1.23 mL, 9.73 mmol) was then added dropwise and the mixture heated at 110° C. for 24 h.
  • the reaction mixture was allowed to cool only briefly and then was quenched by dropwise addition onto ice. When the ice was melted the aqueous layer was extracted several times with Et 2 O.
  • the combined organic extracts were dried over Na 2 SO 4 , filtered and concentrated in vacuo to a yellow solid after storing in the refrigerator overnight. This material was not purified further, but taken on to the next step without further purification.
  • Step C 2-Chloro-5-fluoro-4,6-dimethylpyrimidine was prepared in a manner analogous to Intermediate 55, substituting 2,4,6-trichloro-5-fluoropyrimidine for 2,4-dichloro-5-fluoropyrimidine.
  • 6-Methyl-2-[1,2,3]triazol-2-yl-nicotinic acid To a 100 ml round bottom flask containing 2-chloro-6-methylnicotinic acid (3 g, 17.4 mmol), copper iodide (0.16 g, 0.5 mol %), and cesium carbonate (11.4 g, 35 mmol) was added a mixture of dioxane (20 mL) and H 2 O (0.1 ml, 5.25 mmol).
  • reaction mixture appeared as a cobalt blue slurry which was then diluted with 20 mL ether and 20 mL H 2 O.
  • the resulting solution was thoroughly stirred and transferred to a seperatory funnel then the RBF was subsequently rinsed with 20 mL ether and H 2 O each.
  • the aqueous layer was separated from the organic layer and acidified to pH 1 with 6 mL conc. HCl.
  • the now brown/lime green aqueous layer was extracted twice with EtOAc.
  • the bright yellow organic layers were combined and dried with Na 2 SO 4 and then conc. into a yellow powder under reduced pressure. To the yellow powder was added EtOAc to form a yellow slurry.
  • reaction mixture appeared as a blue slurry which was then diluted with 20 mL ether and 20 mL H 2 O.
  • the resulting solution was thoroughly stirred and transferred to a separatory funnel then the RBF was subsequently rinsed with 20 mL ether and H 2 O each.
  • the aqueous layer was separated from the organic layer and acidified to pH 1 with 6 mL conc. HCl.
  • the now brown/lime green aqueous layer was extracted twice with EtOAc. The bright yellow organic layers were combined and dried with Na 2 SO 4 and then conc.
  • Step A 2-Bromo-3-fluorobenzonitrile (1.0 g, 5.0 mmol) and (1H-pyrazol-5-yl)boronic acid (647 mg, 4.6 mmol) were combined and dissolved in degassed DME (15 mL) then treated with NaHCO 3 (1260 mg, 8.4 mmol) in water and the reaction purged with bubbling N 2 for 5 minutes. The reaction was treated with Pd(PPh 3 ) 4 (288 mg, 0.2 mmol) and then purged with bubbling for 5 minutes in a sealed vessel and then heated to reflux for 2 h. The reaction was then cooled to 23° C. filtered and the solids were rinsed with EtOAc and the layers separated.
  • Step A Methyl-2-fluoro-bromobenzoate (1.0 gram, 4.2 mmol) and (1H-pyrazol-5-yl)boronic acid (485 mg, 4.6 mmol) were combined and dissolved in degassed DME (15 mL) then treated with NaHCO 3 (706 mg, 8.4 mmol) in water and the reaction purged with bubbling N 2 for 5 minutes. The reaction was treated with Pd(PPh 3 ) 4 (243 mg (0.2 mmol) and then purged with bubbling for 5 minutes in a sealed vessel and then heated to reflux for 2 h. The reaction mixture was cooled to 23° C., filtered, and the solid was rinsed with EtOAc and the layers separated. The organic layers were combined, dried and concentrated. Chromatography (ethyl acatate/hexanes, 0-30%) gave methyl 5-fluoro-2-(1H-pyrazol-5-yl)benzoate (415 mg, 44%).
  • Step A 2-Iodo-4-fluorobenzonitrile (2.54 g, 10.3 mmol) and 2-tributylstannane pyrimidine (3.69 g, 10.0 mmol) were dissolved in domethoxyethane (18 mL) and treated with tetrakistriphenylphosphine palladium (0) (578 mg, 0.5 mmol) and copper (I) iodide (95 mg, 0.5 mmol). The reaction was then heated to 160° C. for 90 minutes in the microwave. The reaction was cooled, concentrated under reduced pressure. Chromatography (20-100% EA in hexanes) gave the desired product.
  • Step A 4-Methoxy-2-(pyrimidin-2-yl)benzonitrile was prepared in a manner analogous to Intermediate 87.
  • Step A 1,1,1,3,3,3,5,5-Octadeuteriopentane-2,4-dione.
  • acetylacetone 10 mL, 95.1 mmol
  • D 2 O 90 mL
  • K 2 CO 3 1.0 g, 7.29 mmol
  • the mixture was heated at 120° C. overnight.
  • the aqueous layer was extracted with DCM and the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo to an orange liquid (Frediani et. al., Catalysis Comm. 2, 2001, 125).
  • Step B 2-Deuteriohydroxy-4,4,4,5,6,6,6-septadeuteriopyrimidine.
  • urea-d 4 (0.95 g, 14.82 mmol) followed by 35% wt.
  • DCl in D 2 O (2 mL, 23.71 mmol) The mixture was heated at 90° C. for 36 h, cooled to room temperature and then chilled in an ice bath before filtration and washing of the white solid with cold EtOD to afford the desired product as the DCl salt (1.53 g, 61%).
  • Step C 2-Chloro-4,4,4,5,6,6,6-septadeuteriopyrimidine.
  • 2-deuteriohydroxy-4,4,4,5,6,6,6-septadeuteriopyrimidine product of Step B
  • POCl 3 7.9 mL, 9.04 mmol
  • the mixture was allowed to cool to room temperature and then added to ice drop wise.
  • the aqueous mixture was neutralized to pH 6 in an ice bath with 5 N NaOH.
  • the aqueous layer was extracted with DCM and the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo to afford the desired product as a yellow solid (1.3 g, 96%).
  • a 150 mL EasyMax reactor was fitted with a mechanical stirrer, a reflux condenser and a temperature probe and 2-chloro-4,6-dimethylpyrimidine (7.10 g, 49.8 mmol), potassium carbonate (9.77 g, 70.7 mmol), N-boc-3,7diazabicylco[3.3.0]octane (10.03 g, 47.3 mmol) and 2-propanol (54.2 g) were added. The reaction was slurried at 20° C. for 5 minutes and then the temperature was raised to 80° C. over 30 minutes. The reaction was then stirred at 80° C. for 8 hours, cooled to 20° C. within 30 minutes and allowed to stand overnight.
  • Step A 2-Fluoro-6-iodo-benzoic acid methyl ester.
  • 2-fluoro-6-iodo-benzoic acid 7.5 g, 28.2 mmol
  • LiOH.H 2 O 1.42 g, 33.8 mmol
  • THF 100 mL
  • Dimethyl sulfate 4.03 mL, 42.3 mmol
  • the mixture was warmed to 65° C.
  • the mixture was cooled to room temperature and NH 4 Cl (aq) (50 mL, 13 wt % solution) was added.
  • Step B 2-Fluoro-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester.
  • 2-fluoro-6-iodo-benzoic acid methyl ester 7.29, 26.0 mmol
  • anhydrous THF 150 mL
  • This mixture was cooled to 0° C. and i-PrMgCl (13.7 mL, 2 M in THF, 27.3 mmol) was added dropwise.
  • Step C 2-Fluoro-6-pyrimidin-2-yl-benzoic acid methyl ester.
  • 2-fluoro-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester 5.46 g, 19.5 mmol
  • 2-methyl-THF 50 mL
  • 2-chloropyrimidine 2.68 g, 23.4 mmol
  • sodium carbonate 6.2 g, 58.5 mmol
  • PdCl 2 (dppf)-dcm adduct (CAS#72287-26-4) (1.27 g, 1.56 mmol) was then added and the reaction mixture was warmed to 74° C. and stirred for 2.5 h. After cooling, the mixture was diluted with MTBE (50 mL) and water (80 mL). The layers were thoroughly mixed separated. The aqueous layer was extracted with additional MTBE (100 mL). The combined organics were dried over magnesium sulfate, filtered, concentrated and then purified by flash chromatography (0-25% EA/hexanes) to provide the title compound (1.72 g, 72 wt %, 30% yield).
  • Step D 2-Fluoro-6-pyrimidin-2-yl-benzoic acid.
  • 2-fluoro-6-pyrimidin-2-yl-benzoic acid methyl ester (1.36 g, 5.85 mmol) in 2-methyl-THF (20 mL) was added sodium hydroxide (2 M in water, 9.3 mL, 18.6 mmol).
  • the mixture was heated to 72° C. and stirred for 9 h.
  • the layers were separated and the aqueous layer acified to pH 2 by dropwise addition of 50% HCl (aq) (3.1 mL).
  • 5-Fluoro-2-[1,2,3]triazol-2-yl-benzoic acid To a solution of 5-fluoro-2-iodo-benzoic acid (3.86 g, 14.65 mmol), 2H-[1,2,3]triazole (2.5 g, 36.2 mmol), Cs 2 CO 3 (8.62 g, 24.5 mmol), trans-N,N′-dimethyl-cyclohexane-1,2-diamine (0.4 mL), CuI (244 mg) and DMF (13 mL) were added to a microwave ready vessel and heated to 100° C. for 10 min. The mixture was cooled, diluted with water, and extracted with EtOAc.
  • Examples 16-106, 108-214 were prepared in a manner analogous to Example 15.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US16/391,791 2009-10-23 2010-10-21 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators Active USRE48841E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/391,791 USRE48841E1 (en) 2009-10-23 2010-10-21 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25450909P 2009-10-23 2009-10-23
US13/503,231 US8653263B2 (en) 2009-10-23 2010-10-21 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
PCT/US2010/053606 WO2011050198A1 (en) 2009-10-23 2010-10-21 Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US16/391,791 USRE48841E1 (en) 2009-10-23 2010-10-21 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Publications (1)

Publication Number Publication Date
USRE48841E1 true USRE48841E1 (en) 2021-12-07

Family

ID=43385633

Family Applications (8)

Application Number Title Priority Date Filing Date
US16/391,791 Active USRE48841E1 (en) 2009-10-23 2010-10-21 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US13/503,231 Ceased US8653263B2 (en) 2009-10-23 2010-10-21 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US14/138,941 Active US9079911B2 (en) 2009-10-23 2013-12-23 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US14/734,225 Abandoned US20150335651A1 (en) 2009-10-23 2015-06-09 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS
US15/413,965 Abandoned US20170129901A1 (en) 2009-10-23 2017-01-24 Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
US16/601,832 Active US11059828B2 (en) 2009-10-23 2019-10-15 Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
US17/372,168 Active US11667644B2 (en) 2009-10-23 2021-07-09 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US18/327,990 Pending US20240109901A1 (en) 2009-10-23 2023-06-02 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Family Applications After (7)

Application Number Title Priority Date Filing Date
US13/503,231 Ceased US8653263B2 (en) 2009-10-23 2010-10-21 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US14/138,941 Active US9079911B2 (en) 2009-10-23 2013-12-23 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US14/734,225 Abandoned US20150335651A1 (en) 2009-10-23 2015-06-09 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS
US15/413,965 Abandoned US20170129901A1 (en) 2009-10-23 2017-01-24 Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
US16/601,832 Active US11059828B2 (en) 2009-10-23 2019-10-15 Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
US17/372,168 Active US11667644B2 (en) 2009-10-23 2021-07-09 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US18/327,990 Pending US20240109901A1 (en) 2009-10-23 2023-06-02 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Country Status (38)

Country Link
US (8) USRE48841E1 (it)
EP (3) EP2491038B1 (it)
JP (1) JP5759470B2 (it)
KR (3) KR101859409B1 (it)
CN (1) CN102781942B (it)
AR (2) AR078731A1 (it)
AU (2) AU2010310595B2 (it)
BR (1) BR112012010820B1 (it)
CA (1) CA2778484C (it)
CL (1) CL2010001162A1 (it)
CO (1) CO6541572A2 (it)
CR (1) CR20120273A (it)
CY (2) CY1117743T1 (it)
DK (2) DK2491038T3 (it)
EA (1) EA022766B1 (it)
EC (1) ECSP12011908A (it)
ES (2) ES2735411T3 (it)
HK (2) HK1175463A1 (it)
HR (2) HRP20160781T1 (it)
HU (2) HUE043962T2 (it)
IL (1) IL219234A (it)
JO (2) JO3267B1 (it)
LT (1) LT3093291T (it)
ME (2) ME02437B (it)
MX (1) MX2012004753A (it)
NI (1) NI201200062A (it)
NZ (1) NZ599629A (it)
PE (1) PE20110404A1 (it)
PL (2) PL2491038T3 (it)
PT (2) PT2491038T (it)
RS (2) RS59004B1 (it)
SI (2) SI2491038T1 (it)
SM (1) SMT201600216B (it)
TR (1) TR201910327T4 (it)
TW (1) TWI481613B (it)
UA (1) UA107812C2 (it)
UY (1) UY32966A (it)
WO (1) WO2011050198A1 (it)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
AR088692A1 (es) 2011-11-08 2014-06-25 Actelion Pharmaceuticals Ltd Derivados de 2-(1,2,3-triazol-2-il)benzamina y 3-(1,2,3-triazol-2-il)picolinamida
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
SG11201404738QA (en) 2012-02-07 2014-10-30 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
NZ703448A (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
US9682966B2 (en) * 2012-08-16 2017-06-20 The Scripps Research Institute Kappa opioid ligands
CN104703980B (zh) 2012-10-10 2017-09-22 埃科特莱茵药品有限公司 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
CN103012293A (zh) * 2012-12-13 2013-04-03 同济大学 一种抗失眠药物mk-4305中间体的合成方法
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
CA2917050A1 (en) * 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
AU2014358766B2 (en) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2016020403A1 (en) * 2014-08-04 2016-02-11 Sandoz Ag Preparation of a benzoic acid derivative and its use for the preparation of suvorexant
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
EP3191468B1 (en) 2014-09-11 2018-12-12 Janssen Pharmaceutica NV Substituted 2-azabicycles and their use as orexin receptor modulators
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
US10370380B2 (en) * 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
WO2017088731A1 (zh) * 2015-11-24 2017-06-01 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109219606B (zh) 2016-02-12 2021-10-01 阿斯利康(瑞典)有限公司 食欲素受体调节剂的卤素取代的哌啶
CA3016706A1 (en) * 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
CN105949203B (zh) * 2016-05-24 2018-07-13 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
CN107759620B (zh) * 2016-08-16 2021-11-12 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN108299437B (zh) * 2017-01-13 2022-07-08 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
GB201702174D0 (en) * 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists
MX2019012902A (es) 2017-05-03 2019-12-16 Idorsia Pharmaceuticals Ltd Preparacion de derivados de acido 2-([1,2,3]triazol-2-il)-benzoico .
GB201707499D0 (en) * 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
GB201707504D0 (en) * 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
ES2952332T3 (es) 2017-08-29 2023-10-30 H Lundbeck As Compuestos espirocíclicos y sus métodos de preparación y uso
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos
JP6874217B2 (ja) 2017-09-28 2021-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なｎ−（２，２−ジフルオロエチル）−ｎ−［（ピリミジニルアミノ）プロパニル］アリールカルボキサミド
CN109988169B (zh) * 2017-12-29 2022-02-01 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109988171A (zh) * 2017-12-29 2019-07-09 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109988170B (zh) * 2017-12-29 2022-04-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
WO2020023723A1 (en) * 2018-07-27 2020-01-30 Icahn School Of Medicine At Mount Sinai Method of treating aggression with orexin receptor antagonists
EP3880204B1 (en) * 2018-11-14 2024-05-15 Janssen Pharmaceutica N.V. Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN112142713A (zh) * 2019-06-27 2020-12-29 山东润博生物科技有限公司 一种咪草烟的合成方法
CA3149689A1 (en) * 2019-08-07 2021-02-11 Janssen Pharmaceutica Nv Improved synthetic methods of making (2h-1,2,3-triazol-2-yl)phenyl compounds as orexin receptor modulators
CN112876478B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
WO2021104294A1 (en) * 2019-11-29 2021-06-03 Sunshine Lake Pharma Co., Ltd. CRYSTAL FORMS OF OCTAHYDROPYRROLO [3,4-c] PYRROLE DERIVATIVES
CN112876480B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
CN112876479B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
CN112876481B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
WO2022122009A1 (zh) * 2020-12-11 2022-06-16 苏州晶云药物科技股份有限公司 吡咯类衍生化合物的晶型及其制备方法
AU2022239403A1 (en) * 2021-03-16 2023-09-21 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Nitrogen-containing heterocyclic polycyclic compound, preparation method therefor, and application thereof
CN114063673B (zh) * 2021-11-09 2023-03-03 万华化学集团股份有限公司 一种反应釜温度控制方法、系统及存储介质
CN116217593A (zh) * 2021-12-02 2023-06-06 江苏恩华药业股份有限公司 一种八氢吡咯并[3,4-c]吡咯甲基酮衍生物及其应用
WO2023163964A1 (en) 2022-02-24 2023-08-31 Teva Czech Industries S.R.O. Solid state forms of seltorexant
WO2023180556A1 (en) 2022-03-24 2023-09-28 Janssen Pharmaceutica Nv Methods for treating agitation in subjects with mild cognitive impairment or major neurocognition disorder
TW202409039A (zh) * 2022-07-15 2024-03-01 美商百健Ｍａ公司 依莫帕米結合蛋白抑制劑及其用途
WO2024056016A1 (zh) * 2022-09-14 2024-03-21 江苏豪森药业集团有限公司 含氮杂环的多环化合物的自由碱晶型及其制备方法
CN118556061A (zh) * 2022-11-23 2024-08-27 江苏恩华药业股份有限公司 一种二取代八氢吡咯并[3,4-c]吡咯甲基酮衍生物及其应用
WO2024125395A1 (zh) * 2022-12-12 2024-06-20 江苏恩华药业股份有限公司 一种取代四氢环戊基[c]吡咯衍生物、制备方法、中间体及其应用
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Citations (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085225A (en) 1975-03-20 1978-04-18 U.S. Philips Corporation Oxime ethers having anti-depressive activity
US4136193A (en) 1976-01-14 1979-01-23 Kefalas A/S Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans
WO1996039407A1 (en) 1995-06-06 1996-12-12 Abbott Laboratories Quinolizinone type compounds
WO1997011945A1 (en) 1995-09-26 1997-04-03 Merck Sharp & Dohme Limited Diazabicyclooctane derivatives having selective 5-ht1dalpha antagonist activity
WO2000055143A1 (en) 1999-03-17 2000-09-21 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
WO2001061347A1 (en) 2000-02-14 2001-08-23 Ansys Technologies, Inc. Urine collection cup
WO2001081347A2 (en) 2000-04-27 2001-11-01 Abbott Laboratories Diazabicyclic central nervous system active agents
WO2001085693A1 (fr) 2000-05-11 2001-11-15 Banyu Pharmaceutical Co., Ltd. Dérivés n-acyltétrahydroisoquinoline
US20020019388A1 (en) 2000-04-27 2002-02-14 Schrimpf Michael R. Diazabicyclic central nervous system active agents
WO2002060902A1 (en) 2001-02-02 2002-08-08 Astrazeneca Ab 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2002070527A1 (en) 2001-03-02 2002-09-12 Akzo Nobel N.V. Mass-selective purification of organometallics
WO2003002561A1 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2003002581A1 (en) 2001-06-29 2003-01-09 Pabu Services, Inc. Process for the production of pentaerythritol phosphate alcohol
WO2003051672A1 (en) 2001-12-18 2003-06-26 Christopher Clarke Vehicle imaging system
WO2003051872A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Ethylene diamine derivatives and their use as orexin-receptor antagonists
WO2004004733A1 (en) 2002-07-09 2004-01-15 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
WO2004033418A2 (en) 2002-10-11 2004-04-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
WO2004041791A1 (en) 2002-11-06 2004-05-21 Glaxo Group Limited N-aryl acetyl cyclic amine derivatives as orexin antagonists
WO2004085403A1 (en) 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
WO2004096780A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Quinoxalinone-3- one derivatives as orexin receptor antagonists
US20040242641A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
WO2005005439A1 (en) 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
WO2005023231A1 (en) 2003-09-10 2005-03-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US20050101602A1 (en) 2003-09-19 2005-05-12 Anwer Basha Substituted diazabicycloalkane derivatives
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005084667A1 (en) 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US20060019985A1 (en) 2004-07-22 2006-01-26 Cumbre Inc. Rifamycin derivatives
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
WO2006024779A1 (fr) 2004-08-03 2006-03-09 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en therapeutique
US20060074121A1 (en) 2004-03-03 2006-04-06 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2006052542A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
WO2006056848A1 (en) 2004-11-24 2006-06-01 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
WO2006067121A1 (de) 2004-12-20 2006-06-29 Siemens Aktiengesellschaft Verfahren zur sicheren auslegung eines systems, zugehörige systemkomponente und software
US20060241102A1 (en) 2003-07-25 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. Medicinal compositions
US20060258672A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Multicyclic compounds and methods of their use
US20060258691A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
WO2006123121A1 (en) 2005-05-19 2006-11-23 Chroma Therapeutics Ltd Histone deacetylase inhibitors
WO2007007069A1 (en) 2005-07-07 2007-01-18 Vernalis (R & D) Limited Azacyclic compounds as inhibitors of sensory neurone specific sodium channels
WO2007085718A1 (fr) 2006-01-27 2007-08-02 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en tant qu'antagonistes des recepteurs de l'orexine 2
WO2007088276A2 (fr) 2006-02-02 2007-08-09 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2007092416A2 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007126935A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Diazepan orexin receptor antagonists
WO2007126934A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Amidoethylthioether orexin receptor antagonists
WO2007146761A2 (en) 2006-06-12 2007-12-21 Neurogen Corporation Diaryl pyrimidinones and related compounds
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008008551A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
WO2008008518A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Substituted diazepan orexin receptor antagonists
WO2008020405A2 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds as orexin receptor antagonists
WO2008034731A1 (en) 2006-09-18 2008-03-27 F. Hoffmann-La Roche Ag Octahydropyrrolo [3, 4-c] pyrrole derivatives an their use as antiviral agents
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008067121A2 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
US20080132490A1 (en) 2006-12-01 2008-06-05 Bergman Jeffrey M Substituted diazepan orexin receptor antagonists
WO2008078291A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US20080175795A1 (en) 2005-06-30 2008-07-24 Bexel Pharmaceuticals, Inc. Novel derivatives of amino acids for treatment of obesity and related disorders
WO2008117241A2 (en) 2007-03-26 2008-10-02 Actelion Pharmaceuticals Ltd Thiazolidine derivatives as orexin receptor antagonists
WO2008134480A1 (en) 2007-04-25 2008-11-06 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
WO2009003997A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists
WO2009003993A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009011775A1 (en) 2007-07-13 2009-01-22 Merck & Co., Inc. Amidoethyl alkylamino orexin receptor antagonists
WO2009016286A2 (fr) 2007-06-28 2009-02-05 Sanofi-Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo[1, 2-b]-pyridazine, leur preparation et leur application en therapeutique
US20090036422A1 (en) 2007-08-02 2009-02-05 Henner Knust Monoamide derivatives as orexin receptor antagonists
JP2009506061A (ja) 2005-08-26 2009-02-12 メルク エンド カムパニー インコーポレーテッド ジアザスピロデカンオレキシン受容体拮抗薬
WO2009022311A2 (en) 2007-08-15 2009-02-19 Actelion Pharmaceuticals Ltd 1,2-diamido-ethylene derivatives as orexin antagonists
WO2009037394A2 (fr) 2007-07-19 2009-03-26 Sanofi-Aventis DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
WO2009056238A1 (de) 2007-10-30 2009-05-07 Novega Produktonssysteme Gmbh Ortungsbake
WO2009061197A1 (en) 2007-11-08 2009-05-14 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
US20090163485A1 (en) 2007-12-21 2009-06-25 Henner Knust Heteroaryl derivatives as orexin receptor antagonists
WO2009081197A1 (en) 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
WO2009124956A1 (en) 2008-04-10 2009-10-15 Glaxo Group Limited Pyridine derivatives used to treat orexin related disorders
WO2009145900A1 (en) 2008-05-27 2009-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
WO2010012620A1 (en) 2008-07-29 2010-02-04 F. Hoffmann-La Roche Ag Pyrrolidin-3-ylmethyl-amine as orexin antagonists
US20100029617A1 (en) 2006-08-28 2010-02-04 Actelion Pharmaceuticals Ltd. 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists
WO2010017260A1 (en) 2008-08-07 2010-02-11 Merck & Co., Inc. Tripyridyl carboxamide orexin receptor antagonists
WO2010048010A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048012A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048013A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
WO2010048017A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
WO2010048014A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
WO2010051238A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
WO2010051237A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010060472A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
US20100144760A1 (en) 2008-12-02 2010-06-10 Giuseppe Alvaro Novel compounds
WO2010063662A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
US20100160345A1 (en) 2008-10-09 2010-06-24 Giuseppe Alvaro Novel compounds
US20100160344A1 (en) 2008-10-09 2010-06-24 Giuseppe Alvaro Novel compounds
WO2010072722A1 (en) 2008-12-23 2010-07-01 Glaxo Group Limited Piperidine derivatives useful as orexin antagonists
WO2010098911A2 (en) 2009-02-26 2010-09-02 Microsoft Corporation Dynamic rear-projected user interface
US7812031B2 (en) 2004-02-10 2010-10-12 Sanofi-Aventis Pyrimidine derivatives as orexin receptor antagonists
US20100267730A1 (en) 2008-10-09 2010-10-21 Giuseppe Alvaro Novel compounds
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
US7834028B2 (en) 2006-04-26 2010-11-16 Actelion Pharmaceuticals Ltd. Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
WO2011023578A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
WO2011023585A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011057471A1 (en) 2009-11-10 2011-05-19 Center Laboratories, Inc. Methods and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
US20110152235A1 (en) 2009-12-23 2011-06-23 Jasco Pharmaceuticals, LLC Aminopyrimidine Kinase Inhibitors
US8106215B2 (en) 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
WO2012081692A1 (ja) 2010-12-17 2012-06-21 大正製薬株式会社 ピラゾール誘導体
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
US8288429B2 (en) 2007-07-27 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.3.0]octane derivatives
WO2012153729A1 (ja) 2011-05-10 2012-11-15 大正製薬株式会社 ヘテロ芳香環誘導体
WO2013005755A1 (ja) 2011-07-05 2013-01-10 大正製薬株式会社 メチルピペリジン誘導体
US8357700B2 (en) 2008-10-21 2013-01-22 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
US8362009B2 (en) 2007-10-29 2013-01-29 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
WO2013187467A1 (ja) 2012-06-15 2013-12-19 大正製薬株式会社 ヘテロ芳香環メチル環状アミン誘導体
WO2013187466A1 (ja) 2012-06-15 2013-12-19 大正製薬株式会社 分岐鎖アルキルヘテロ芳香環誘導体
JP2014015452A (ja) 2012-06-15 2014-01-30 Taisho Pharmaceutical Co Ltd ピラゾール誘導体を含有する医薬
US8653263B2 (en) 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2014091876A1 (ja) 2012-12-13 2014-06-19 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2014111586A (ja) 2012-11-09 2014-06-19 Taisho Pharmaceutical Co Ltd ヘテロ芳香環誘導体を含有する医薬
JP2014141480A (ja) 2012-12-28 2014-08-07 Taisho Pharmaceutical Co Ltd メチルピペリジン誘導体を含有する医薬
US8877773B2 (en) 2009-10-24 2014-11-04 Indiana University Research And Technology Corporation Methods for treating chronic obstructive pulmonary disease
US20140364433A1 (en) 2012-02-07 2014-12-11 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US20150018309A1 (en) 2012-02-23 2015-01-15 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US9029364B2 (en) 2011-10-21 2015-05-12 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
WO2015085004A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
JP2015131802A (ja) 2013-12-13 2015-07-23 大正製薬株式会社 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬
JP2015131803A (ja) 2013-12-13 2015-07-23 大正製薬株式会社 ヘテロ芳香環メチル環状アミン誘導体を含有する医薬
WO2015123355A1 (en) 2014-02-12 2015-08-20 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
WO2015152368A1 (ja) 2014-04-04 2015-10-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
WO2015152367A1 (ja) 2014-04-04 2015-10-08 大正製薬株式会社 オキソ複素環誘導体
WO2015180060A1 (zh) 2014-05-28 2015-12-03 杭州普晒医药科技有限公司 一种二氮杂环庚烷化合物的盐及其晶型与无定型物
WO2016025669A1 (en) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US9586934B2 (en) 2013-12-09 2017-03-07 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-methyl orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
US9624197B2 (en) 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
US9695163B2 (en) 2013-08-08 2017-07-04 Merck Sharp & Dohme Corp Thiazole orexin receptor antagonists
US9845333B2 (en) 2013-03-13 2017-12-19 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US10828302B2 (en) * 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10226943A1 (de) 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
US9617246B2 (en) 2013-12-18 2017-04-11 Merck Sharp & Dohme Corp. Thioether-piperidinyl orexin receptor antagonists
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US20160051533A1 (en) 2014-08-20 2016-02-25 Ladd Research LLC Diagnosis and pharmacological treatment of seasonal affective disorder and symptoms of seasonality
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
GB201820458D0 (en) 2018-12-14 2019-01-30 Heptares Therapeutics Ltd Ox1 antagonists

Patent Citations (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085225A (en) 1975-03-20 1978-04-18 U.S. Philips Corporation Oxime ethers having anti-depressive activity
US4136193A (en) 1976-01-14 1979-01-23 Kefalas A/S Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans
WO1996039407A1 (en) 1995-06-06 1996-12-12 Abbott Laboratories Quinolizinone type compounds
WO1997011945A1 (en) 1995-09-26 1997-04-03 Merck Sharp & Dohme Limited Diazabicyclooctane derivatives having selective 5-ht1dalpha antagonist activity
WO2000055143A1 (en) 1999-03-17 2000-09-21 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
WO2001061347A1 (en) 2000-02-14 2001-08-23 Ansys Technologies, Inc. Urine collection cup
JP2003531210A (ja) 2000-04-27 2003-10-21 アボット・ラボラトリーズ ジアザビシクロ系中枢神経系活性薬剤
US20020019388A1 (en) 2000-04-27 2002-02-14 Schrimpf Michael R. Diazabicyclic central nervous system active agents
WO2001081347A2 (en) 2000-04-27 2001-11-01 Abbott Laboratories Diazabicyclic central nervous system active agents
WO2001085693A1 (fr) 2000-05-11 2001-11-15 Banyu Pharmaceutical Co., Ltd. Dérivés n-acyltétrahydroisoquinoline
EP1288202A1 (en) 2000-05-11 2003-03-05 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
US6838465B2 (en) 2000-05-11 2005-01-04 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
WO2002060902A1 (en) 2001-02-02 2002-08-08 Astrazeneca Ab 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias
WO2002070527A1 (en) 2001-03-02 2002-09-12 Akzo Nobel N.V. Mass-selective purification of organometallics
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2003002561A1 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2003002581A1 (en) 2001-06-29 2003-01-09 Pabu Services, Inc. Process for the production of pentaerythritol phosphate alcohol
WO2003051672A1 (en) 2001-12-18 2003-06-26 Christopher Clarke Vehicle imaging system
WO2003051872A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Ethylene diamine derivatives and their use as orexin-receptor antagonists
WO2004004733A1 (en) 2002-07-09 2004-01-15 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
US7435815B2 (en) 2002-10-11 2008-10-14 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
WO2004033418A2 (en) 2002-10-11 2004-04-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
US7279578B2 (en) 2002-10-11 2007-10-09 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
WO2004041791A1 (en) 2002-11-06 2004-05-21 Glaxo Group Limited N-aryl acetyl cyclic amine derivatives as orexin antagonists
WO2004085403A1 (en) 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
US20060178515A1 (en) 2003-03-26 2006-08-10 Hamed Aissaoui Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
US7538109B2 (en) 2003-04-28 2009-05-26 Actelion Pharmaceuticals Ltd Quinoxalin-3-one derivatives as orexin receptor antagonists
WO2004096780A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Quinoxalinone-3- one derivatives as orexin receptor antagonists
US20040242641A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
WO2005005439A1 (en) 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20060241102A1 (en) 2003-07-25 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. Medicinal compositions
WO2005023231A1 (en) 2003-09-10 2005-03-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US20050101602A1 (en) 2003-09-19 2005-05-12 Anwer Basha Substituted diazabicycloalkane derivatives
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US7812031B2 (en) 2004-02-10 2010-10-12 Sanofi-Aventis Pyrimidine derivatives as orexin receptor antagonists
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US7763638B2 (en) 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US20100256182A1 (en) 2004-03-01 2010-10-07 Hamed Aissaoui Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
WO2005084667A1 (en) 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20060074121A1 (en) 2004-03-03 2006-04-06 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20060019985A1 (en) 2004-07-22 2006-01-26 Cumbre Inc. Rifamycin derivatives
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
US7396958B2 (en) 2004-08-03 2008-07-08 Sanofi Aventis Sulphonamide derivatives, their preparation and their therapeutic application
WO2006024779A1 (fr) 2004-08-03 2006-03-09 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2006052542A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
US20080009477A1 (en) 2004-11-04 2008-01-10 Neurogen Corporation Arylalkyl Ureas As Cb1 Antagonists
WO2006056848A1 (en) 2004-11-24 2006-06-01 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
WO2006067121A1 (de) 2004-12-20 2006-06-29 Siemens Aktiengesellschaft Verfahren zur sicheren auslegung eines systems, zugehörige systemkomponente und software
US20060258672A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Multicyclic compounds and methods of their use
US20060258691A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
WO2006124748A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Multicyclic compounds and methods of their use
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
WO2006123121A1 (en) 2005-05-19 2006-11-23 Chroma Therapeutics Ltd Histone deacetylase inhibitors
US7932246B2 (en) 2005-05-19 2011-04-26 Chroma Therapeutics Ltd. Histone deacetylase inhibitors
US20080175795A1 (en) 2005-06-30 2008-07-24 Bexel Pharmaceuticals, Inc. Novel derivatives of amino acids for treatment of obesity and related disorders
WO2007007069A1 (en) 2005-07-07 2007-01-18 Vernalis (R & D) Limited Azacyclic compounds as inhibitors of sensory neurone specific sodium channels
US20090176789A1 (en) 2005-08-26 2009-07-09 Breslin Michael J Diazaspirodecane orexin receptor antagonists
JP2009506061A (ja) 2005-08-26 2009-02-12 メルク エンド カムパニー インコーポレーテッド ジアザスピロデカンオレキシン受容体拮抗薬
WO2007085718A1 (fr) 2006-01-27 2007-08-02 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en tant qu'antagonistes des recepteurs de l'orexine 2
US7968534B2 (en) 2006-01-27 2011-06-28 Sanofi-Aventis Sulfonamide derivatives, preparation thereof and use thereof as antagonists of orexin 2 receptors
WO2007088276A2 (fr) 2006-02-02 2007-08-09 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en therapeutique
US20090054439A1 (en) 2006-02-02 2009-02-26 Sanofi-Aventis Sulfonamide derivatives, preparation and therapeutic application thereof
US7956049B2 (en) 2006-02-06 2011-06-07 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007092416A2 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007126935A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Diazepan orexin receptor antagonists
WO2007126934A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Amidoethylthioether orexin receptor antagonists
US7834028B2 (en) 2006-04-26 2010-11-16 Actelion Pharmaceuticals Ltd. Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
WO2007146761A2 (en) 2006-06-12 2007-12-21 Neurogen Corporation Diaryl pyrimidinones and related compounds
WO2008008518A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Substituted diazepan orexin receptor antagonists
WO2008008551A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
US7994336B2 (en) 2006-08-15 2011-08-09 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
WO2008020405A2 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds as orexin receptor antagonists
US20100029617A1 (en) 2006-08-28 2010-02-04 Actelion Pharmaceuticals Ltd. 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists
WO2008034731A1 (en) 2006-09-18 2008-03-27 F. Hoffmann-La Roche Ag Octahydropyrrolo [3, 4-c] pyrrole derivatives an their use as antiviral agents
US20100016401A1 (en) 2006-09-29 2010-01-21 Actelion Phamaceuticals Ltd. 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20140107084A1 (en) 2006-10-25 2014-04-17 Procom One, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20090306100A1 (en) 2006-11-07 2009-12-10 Joseph Barbosa Methods of treating schizophrenia
WO2008067121A2 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
US20080153811A1 (en) 2006-11-07 2008-06-26 Joseph Barbosa Methods of Treating Cognitive Impairment and Dementia
US7951797B2 (en) 2006-12-01 2011-05-31 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
US20080132490A1 (en) 2006-12-01 2008-06-05 Bergman Jeffrey M Substituted diazepan orexin receptor antagonists
US20130005655A1 (en) 2006-12-06 2013-01-03 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
WO2008078291A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US8188082B2 (en) 2006-12-22 2012-05-29 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives
WO2008117241A2 (en) 2007-03-26 2008-10-02 Actelion Pharmaceuticals Ltd Thiazolidine derivatives as orexin receptor antagonists
US8236964B2 (en) 2007-03-26 2012-08-07 Actelion Pharmaceuticals Ltd. Thiazolidine derivatives as orexin receptor antagonists
WO2008134480A1 (en) 2007-04-25 2008-11-06 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
US7973159B2 (en) 2007-04-25 2011-07-05 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
WO2009016286A2 (fr) 2007-06-28 2009-02-05 Sanofi-Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo[1, 2-b]-pyridazine, leur preparation et leur application en therapeutique
WO2009003997A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists
US20100210667A1 (en) 2007-07-03 2010-08-19 Giuseppe Alvaro Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists
US20120095034A1 (en) 2007-07-03 2012-04-19 Giuseppe Alvaro Piperidine derivatives useful as orexin receptor antagonists
US8106215B2 (en) 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
WO2009003993A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
US20090022670A1 (en) 2007-07-03 2009-01-22 Giuseppe Alvaro Novel compounds
US8067420B2 (en) 2007-07-06 2011-11-29 Bristol-Myers Squibb Company Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods
US8012984B2 (en) 2007-07-06 2011-09-06 Bristol-Myers Squibb Company Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009009501A2 (en) 2007-07-06 2009-01-15 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009011775A1 (en) 2007-07-13 2009-01-22 Merck & Co., Inc. Amidoethyl alkylamino orexin receptor antagonists
WO2009037394A2 (fr) 2007-07-19 2009-03-26 Sanofi-Aventis DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
US8288429B2 (en) 2007-07-27 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.3.0]octane derivatives
US20090036422A1 (en) 2007-08-02 2009-02-05 Henner Knust Monoamide derivatives as orexin receptor antagonists
WO2009016087A1 (en) 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag Monoamide derivatives as orexin receptor antagonists
WO2009022311A2 (en) 2007-08-15 2009-02-19 Actelion Pharmaceuticals Ltd 1,2-diamido-ethylene derivatives as orexin antagonists
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
US8362009B2 (en) 2007-10-29 2013-01-29 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
WO2009056238A1 (de) 2007-10-30 2009-05-07 Novega Produktonssysteme Gmbh Ortungsbake
WO2009061197A1 (en) 2007-11-08 2009-05-14 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
US20090163485A1 (en) 2007-12-21 2009-06-25 Henner Knust Heteroaryl derivatives as orexin receptor antagonists
WO2009081197A1 (en) 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
US20110053979A1 (en) 2008-04-10 2011-03-03 Giuseppe Alvaro Pyridine derivatives used to treat orexin related disorders
WO2009124956A1 (en) 2008-04-10 2009-10-15 Glaxo Group Limited Pyridine derivatives used to treat orexin related disorders
WO2009145900A1 (en) 2008-05-27 2009-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
US9168258B2 (en) 2008-05-27 2015-10-27 Intra-Cellular Therapries, Inc. Methods and compositions for sleep disorders and other disorders
US20160030425A1 (en) 2008-05-27 2016-02-04 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
US8598119B2 (en) 2008-05-27 2013-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
US8748430B2 (en) 2008-07-29 2014-06-10 Hoffmann-La Roche Inc Pyrrolidin-3yl-methylamine quinoxaline derivatives
US7923470B2 (en) 2008-07-29 2011-04-12 Hoffmann-La Roche Inc. Benzooxazoles as orexin antagonists
WO2010012620A1 (en) 2008-07-29 2010-02-04 F. Hoffmann-La Roche Ag Pyrrolidin-3-ylmethyl-amine as orexin antagonists
US8207220B2 (en) 2008-07-29 2012-06-26 Hoffmann-La Roche Inc. Substituted benzothiazoles as orexin antagonists
WO2010017260A1 (en) 2008-08-07 2010-02-11 Merck & Co., Inc. Tripyridyl carboxamide orexin receptor antagonists
US20100267730A1 (en) 2008-10-09 2010-10-21 Giuseppe Alvaro Novel compounds
US20100160344A1 (en) 2008-10-09 2010-06-24 Giuseppe Alvaro Novel compounds
US20100160345A1 (en) 2008-10-09 2010-06-24 Giuseppe Alvaro Novel compounds
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
US20110288098A1 (en) 2008-10-09 2011-11-24 Glaxo Group Limited Novel compounds
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
US8623863B2 (en) 2008-10-21 2014-01-07 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
WO2010048014A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
WO2010048010A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048017A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
US8357700B2 (en) 2008-10-21 2013-01-22 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
WO2010048013A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
WO2010048012A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010051238A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
WO2010051237A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010060472A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
US20100144760A1 (en) 2008-12-02 2010-06-10 Giuseppe Alvaro Novel compounds
US8133908B2 (en) 2008-12-02 2012-03-13 Glaxo Group Limited Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine
WO2010063663A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
WO2010063662A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
US20110257198A1 (en) 2008-12-23 2011-10-20 Giuseppe Alvaro Piperidine derivatives useful as orexin antagonists
WO2010072722A1 (en) 2008-12-23 2010-07-01 Glaxo Group Limited Piperidine derivatives useful as orexin antagonists
WO2010098911A2 (en) 2009-02-26 2010-09-02 Microsoft Corporation Dynamic rear-projected user interface
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
US20120040991A1 (en) 2009-04-24 2012-02-16 Glaxo Group Limited 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
US20120149711A1 (en) 2009-08-24 2012-06-14 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
US20120149723A1 (en) 2009-08-24 2012-06-14 Romano Di Fabio 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
WO2011023585A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
WO2011023578A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
US8653263B2 (en) 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US20150335651A1 (en) 2009-10-23 2015-11-26 Janssen Pharmaceutica Nv DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US20170129901A1 (en) 2009-10-23 2017-05-11 Janssen Pharmaceutica Nv Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
AU2010310595B2 (en) 2009-10-23 2015-07-16 Janssen Pharmaceutica Nv Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
US9079911B2 (en) 2009-10-23 2015-07-14 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US8877773B2 (en) 2009-10-24 2014-11-04 Indiana University Research And Technology Corporation Methods for treating chronic obstructive pulmonary disease
US20150011613A1 (en) 2009-10-24 2015-01-08 Indiana University Research And Technology Corporation Methods and compositions for panic disorders
US20130210911A1 (en) 2009-11-10 2013-08-15 Center Laboratories, Inc. Method and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
WO2011057471A1 (en) 2009-11-10 2011-05-19 Center Laboratories, Inc. Methods and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
US8563539B2 (en) 2009-12-23 2013-10-22 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
US20110152235A1 (en) 2009-12-23 2011-06-23 Jasco Pharmaceuticals, LLC Aminopyrimidine Kinase Inhibitors
US9157077B2 (en) 2009-12-23 2015-10-13 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
US20130281465A1 (en) 2010-12-17 2013-10-24 Taisho Pharmaceutical Co., Ltd. Pyrazole derivative
EP2653469A1 (en) 2010-12-17 2013-10-23 Taisho Pharmaceutical Co., Ltd. Pyrazole derivative
WO2012081692A1 (ja) 2010-12-17 2012-06-21 大正製薬株式会社 ピラゾール誘導体
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
WO2012153729A1 (ja) 2011-05-10 2012-11-15 大正製薬株式会社 ヘテロ芳香環誘導体
EP2708537A1 (en) 2011-05-10 2014-03-19 Taisho Pharmaceutical Co., Ltd. Heteroaromatic ring derivative
US20140081025A1 (en) 2011-05-10 2014-03-20 Taisho Pharmaceutical Co., Ltd. Heteroaromatic ring derivative
US20140228377A1 (en) 2011-07-05 2014-08-14 Taisho Pharmaceutical Co., Ltd. Methylpiperidine derivative
EP2730573A1 (en) 2011-07-05 2014-05-14 Taisho Pharmaceutical Co., Ltd. Methylpiperidine derivative
WO2013005755A1 (ja) 2011-07-05 2013-01-10 大正製薬株式会社 メチルピペリジン誘導体
US9029364B2 (en) 2011-10-21 2015-05-12 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
US20140364432A1 (en) 2012-02-07 2014-12-11 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US20140364433A1 (en) 2012-02-07 2014-12-11 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US20150018309A1 (en) 2012-02-23 2015-01-15 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP2862855A1 (en) 2012-06-15 2015-04-22 Taisho Pharmaceutical Co., Ltd. Branched chain alkyl heteroaromatic ring derivative
EP2862860A1 (en) 2012-06-15 2015-04-22 Taisho Pharmaceutical Co., Ltd. Heteroaromatic methyl cyclic amine derivative
US20150166523A1 (en) 2012-06-15 2015-06-18 Taisho Pharmaceutical Co., Ltd. Branched chain alkyl heteroaromatic ring derivative
US20150183768A1 (en) 2012-06-15 2015-07-02 Taisho Pharmaceutical Co., Ltd. Heteroaromatic methyl cyclic amine derivative
JP2014015452A (ja) 2012-06-15 2014-01-30 Taisho Pharmaceutical Co Ltd ピラゾール誘導体を含有する医薬
WO2013187466A1 (ja) 2012-06-15 2013-12-19 大正製薬株式会社 分岐鎖アルキルヘテロ芳香環誘導体
US9266870B2 (en) 2012-06-15 2016-02-23 Taisho Pharmaceutical Co., Ltd Heteroaromatic methyl cyclic amine derivative
WO2013187467A1 (ja) 2012-06-15 2013-12-19 大正製薬株式会社 ヘテロ芳香環メチル環状アミン誘導体
JP2014111586A (ja) 2012-11-09 2014-06-19 Taisho Pharmaceutical Co Ltd ヘテロ芳香環誘導体を含有する医薬
US9624197B2 (en) 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
JP2016028017A (ja) 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
WO2014091876A1 (ja) 2012-12-13 2014-06-19 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2014141480A (ja) 2012-12-28 2014-08-07 Taisho Pharmaceutical Co Ltd メチルピペリジン誘導体を含有する医薬
US9845333B2 (en) 2013-03-13 2017-12-19 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9695163B2 (en) 2013-08-08 2017-07-04 Merck Sharp & Dohme Corp Thiazole orexin receptor antagonists
WO2015085004A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
US9586934B2 (en) 2013-12-09 2017-03-07 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-methyl orexin receptor antagonists
JP2015131802A (ja) 2013-12-13 2015-07-23 大正製薬株式会社 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬
JP2015131803A (ja) 2013-12-13 2015-07-23 大正製薬株式会社 ヘテロ芳香環メチル環状アミン誘導体を含有する医薬
WO2015123355A1 (en) 2014-02-12 2015-08-20 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
WO2015152367A1 (ja) 2014-04-04 2015-10-08 大正製薬株式会社 オキソ複素環誘導体
WO2015152368A1 (ja) 2014-04-04 2015-10-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
WO2015180060A1 (zh) 2014-05-28 2015-12-03 杭州普晒医药科技有限公司 一种二氮杂环庚烷化合物的盐及其晶型与无定型物
WO2016025669A1 (en) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US10828302B2 (en) * 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists

Non-Patent Citations (178)

* Cited by examiner, † Cited by third party
Title
Aissaoui et al., "N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists", Bioorganic & Medicinal Chemistry Letters, Nov. 2008, 18, 5729-5733.
Arendt et al., "Anxiolytic function of the orexin 2/hypocretin A receptor in the basolateral amygdala", Psychoneuroendocrinology, Feb. 2014, 40, 17-26.
Asnis et al., "Zolpidem for persistent insomnia in SSRI-treated depressed patients", J. Clin. Psychiatry, Oct. 1999, 60(10), 668-676.
Aston-Jones, G. et al., "Role of lateral hypothalamic orexin neurons in reward processing and addiction" Neuropharmacology 2009, 56 Supp.l 1:pp. 112-121.
Bagshawe, K. "Antibody-Directed Enzyme Prodrug Therapy: A Review" Drug Development Research 34:220-230.
Bagshawe, K., "Antibody-Directed Enzyme Prodrug Therapy: A Review" Drug Development Research 34:220-230, 1995.
Baxter et al., "The First Large-Scale Synthesis of MK-4305: A Dual Orexin Receptor Antagonist for the Treatment of Sleep Disorder", Organic Process Research & Development, Mar. 2011, 15, 367-375.
Berg, S. et al., "Pharmaceutical Salts" Journ. of Pharm Sciences, 1977, 66:1-19, & Handbook of Pharmaceutical Salts, Properties, Selection & Use, Stahl and Wermuth, Eds., VViley-VCH and VHCA, Zurich.
Berge, S. et al., "Pharmaceutical Salts" Journ. of Pharm. Sciences, 1977, 66:1-19, & Handbook of Pharmaceutical Salts, Properties, Selection & Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich.
Bergman et al., "Proline bis-amides as potent dual orexin receptor antagonists", Bioorganic & Medicinal Chemistry Letters, Feb. 2008, 18, 1425-1430.
Bertolini, G., et al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolife of Leflunomide, a Potent Immunosuppressive Drug", J. Med. Chem 1997, 40, 2011-2016.
Bertolini, G., et al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug", J. Med. Chem 1997, 40, 2011-2016.
Betschart et al., "Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia", Journal of Medicinal Chemistry, Oct. 2013, 56, 7590-7607.
Bettica et al., "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist", Journal of Psychopharmacology, Aug. 2012, 26(8), 1058-1070.
Bettica et al., "The Orexin Antagonist Sb-649868 Promotes and Maintains Sleep in Men with Primary Insomnia", Sleep, Aug. 2012, 35(8), 1097-1104.
Bodor, N., "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems", Advanced Drug Res., 1984 13, 224-331.
Bodor, N., "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems", Advanced Drug Res., 1984 13, 255-331.
Boss et al. "Biomedical Appl.ication of Orexin/Hypocretin Receptor Ligands in Neuroscience", J. Med. Chem., 2009, 52(4), pp. 891-903.
Brisbare-Roch et al. "Promotion of sleep by targeting the orexin system in rats, dogs and humans", Nature Medicine, 2007, 13, pp. 150-155.
Brisbare-Roch et al., "Promotion of sleep by targeting the orexin system in rats, dogs and humans", Nature Medicine, Feb. 2007, 13(2), 150-155.
Brosschot et al., "The perseverative cognition hypothesis: a review of worry, prolonged stress-related physiological activation, and health", J. Psychosomatic Res., Feb. 2006, 60, 113-124.
Brosschot, "Markers of chronic stress: prolonged physiological activation and (un)conscious perseverative cognition", neuroscience and Behavioral Rev., Sep. 2010, 35, 46-50.
Brucite, Van Nostrand's Encyclopedia of Chemistry, 5th ed., Considine, G.D., ed., 2005, 261.
Bundgaard, H. (Ed.) "Design of Prodrugs" Elsevier, 1985.
Bundgaard, H. (Ed.), "Design of Prodrugs", Elsevier, 1985, 4 pages.
Chang et al., "Inhibitory effects of an orexin-2 receptor antagonist on orexin A- and stress-induced ACTH responses in conscious rats", Neuroscience Res., Mar. 2007, 57, 462-466.
Chemelli et al. "Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation", Cell 1999, 98, pp. 437-451.
Chemelli et al., "Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation", Cell, Aug. 1999, 98, 437-451.
Chen et al. "Pressor effects of orexins injected intracistemally and to rostral ventrolateral medulla of anesthetized rats", Am. J. Physiol., 2000, 278, pp. R692-R697.
Chen et al. "Pressor effects of orexins injected intracisternally and to rostral ventrolateral medulla of anesthetized rats", Am. J. Physiol., 2000, 278, pp. R692-R697.
Chen et al., "The Hypocretin/orexin system: An increasingly important role in neuropsychiatry", Medicinal Research reviews, Jan. 2015, 35(1), 152-197.
Chilean Application No. 1162-2010: Exam Report date stamped May 9, 2012, 6 pages.
Chilean Exam Report CL App. No. 1162-2010, dated Sep. 5, 2012.
Christopher, "Small-molecule antagonists of the orexin receptors", Pharmaceutical Patent Analyst, Pharm. Pat. Anal., Nov. 2014, 3(6), 625-638.
Coleman et al "Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat" Bioorganic & Medicinal Chemistry Letters, 2010, 20 pp. 4201-4205.
Coleman et al., "Discovery of [(2R,5R)-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting Properties", Chem Med Chem, Mar. 2012, 7, 415-424.
Coleman et al."Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists" Bioorganic & Medicinal Chemistry Letters, 2010, 20 pp. 2311-2315.
Considine, G.D., ed., Van Nostrand's Encyclopedia of Chemistry, 5th ed. 2005 p. 261.
Covington et al., Handbook of Chemistry and Physics, 84th ed., 2003-2004 pp. 8-37 to 8-44.
Cox et al., "Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding", Bioorganic & Medicinal Chemistry Letters, Jun. 2009, 19, 2997-3001.
Cox et al., "Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-meth- yl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia" Journal of Medicinal Chemistry 2010. 53(14):pp. 5320-5332.
Cox et al., Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding, Bioorganic & Medicinal Chemistry Letters, 2009, 19 pp. 2997-3001.
Cruz et al., "Interaction study between almorexant, a dual orexin receptor antagonist, and desipramine in healthy male subjects", European Neuropsychopharmacology, Aug. 2010, Vo. 20, Suppl. 3, S253, Abstract No. P.1.c.032.
Cruz et al., "Interaction study between almorexant, a dual orexin receptor antagonist, and desipramine in healthy male subjects", European Neuropsychopharmacology, Aug. 2010, vol. 20, Suppl. 3, S253, Abstract No. P.1.C.032.
Dayas, C. V. et al., "Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse" Biological Psychiatry 2008, 63(2):152-157.
Dayas, C. V. et al., "Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse", Biological Psychiatry, Jan. 2008, 63(2),152-157.
De Lecea et al., "Optogenetic control of hypocretin/orexin neurons", Abstracts of Papers, 248th ACS National Meeting & Exposition, Aug. 2014, 1 page.
De Lecea et al., "The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity", Proc. Natl. Acad. Sci., Jan. 1998, 95, 322-327.
Difabio et al., "Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders", Bioorganic & Medicinal Chemistry Letters, Sep. 2011, 21, 5562-5567.
Dugovic et al., "Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat", The Journal of Pharmacology and Experimental Therapeutics, Jul. 2009, 330(1), 142-151.
Dugovic et al., "Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism", Frontiers in Neuroscience, Feb. 2014, vol. 8, Article 29, 1-8.
Dugovic, C. et al., "Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat" Journal of Pharmacology & Experimental Therapeutics 2009, 330(1) pp. 142-151.
EP Communication, based on EP App. No. 10773477, dated Apr. 19, 2013.
European Patent Application. No. 10773477.4: Communication pursuant to Article 94(3) EPC dated Apr. 19, 2013, 3 pages.
Feng et al., "Brain orexins and wake regulation in rats exposed to maternal deprivation", Brain Research, Jun. 2007, 1154, 163-172.
Fitch et al., "LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy", Frontiers in Neuroscience, Jan. 2014, 8, Article 5, 11 pages.
Fleisher, D. et al., "Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs", Advanced Drug Delivery Reviews, 1996, 19:115-130.
Fleisher, D. et al., "Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs", Advanced Drug Delivery Reviews, May 1996, 19, 115-130.
Frost, J., et al., "Synthesis and Structure-Activity Relationships of 3,8-Diazabicylclo [4.2.0] Octane Ligands, Pitent Nicotinic Acetylcholine Receptor Agonists" J. Med. Chem. 2006, 49, 7843-7853.
Frost, J., et al., "Synthesis and Structure-Activity Relationships of 3,8-Diazabicylclo [4.2.0] Octane Ligands, Potent Nicotinic Acetylcholine Receptor Agonists" J. Med. Chem. 2006, 49, 7843-7853.
Fujimoto et al., "Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists", Bioorganic & Medicinal Chemistry Letters, Nov. 2011, 21, 6414-6416.
Fujimoto et al., "Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists", Nov. 2011, 21, 6409-6413.
Gaffield et al., "Orexin Receptor Antagonists: A New Concept in CNS Disorders?", Chem Med Chem, Aug. 2010, 5, 1197-1214.
Georgescu, D. et al., "Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal" Journal of Neuroscience 2003, 23(8), pp. 3106-3111.
Girardin et al., "Convergent Kilogram-Scale Synthesis of Dual Orexin Receptor Antagonist", Organic Process Research & Development, Jan. 2013, 17, 61-68.
Goldberg et al., "The importance of anxiety in both major depression and bipolar disorder", Depression and Anxiety, Jan. 2012, 29, 471-478.
Gotter et al., "International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology", Pharmacological Reviews, Jul. 2012, 64(3), 389-420.
Gotter et al., "Orexin receptors as therapeutic drug targets", Progress in Brain Research, 2012, 198, 163-188.
Gozzi et al., "Functional Magnetic Resonance Imaging Reveals Different Neural Substrates for the Effects of Orexin-1 and Orexin-2 Receptor Antagonists", PLoS One, Jan. 2011, 6(1), e16406, 12 pages.
Gulbahar et al., "P-169, Plasma Orexin-A Levels of Patients With Major Depression", Turkish Journal of Biochemistry, 22th National Biochemistry Congress, Oct. 27-30, 2010, vol. 35, Issue 1, 2 pages.
Hamlin, A. S. et al., "The neural correlates and role of D1 dopamine receptors in renewal of extinguished alcohol-seeking" Neuroscience 2007, 146(2) pp. 525-536.
Hara et al. "Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity", Neuron, 2001, 30 (2), pp. 345-354.
Hassani et al., "Orexin Neurons Respond Differentially to Auditory Cues Associated with Appetitive versus Aversive Outcomes", J. Neuroscience, Feb. 2016, 36(5), 1747-1757.
Hirose et al., "N-Acyl 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline: The First Orexin-2 Receptor Selective Non-peptidic Antagonist", Bioorganic & Medicinal Chemistry Letters, Dec. 2003, 13, 4497-4499.
International Search Report and Written Opinion dated Jun. 6, 2017 issued in International Patent Application No. PCT/US17/21565.
International Search Report dated Jan. 12, 2011, Int'l. App. No. PCT/US2010/053606, filing date: Oct. 21, 2010.
J.H. Poupaert, Drug Design: Basic Principles and Applications, in 2 Encyclopedia of Pharmaceutical Technology 1362-1369 (James Swarbrick ed., 3rd ed., 2007).
Jiang et al., "Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists", Bioorganic & Medicinal Chemistry Letters, Jun. 2012, 22, 3890-3894.
Johnson et al., "A key role for orexin in panic anxiety", Nature Medicine, Jan. 2010, vol. 16, No. 1, 111-115.
Johnson et al., "Orexin, stress, and anxiety/panic states", Progress in Brain Research, 2012, 198, 133-161.
Kane, J.K. et al., "Hypothalamic orexin-A binding sites are downregulated by chronic nicotine treatment in the rat" Neuroscience Letters 2001, 298(1):pp. 1-4.
Kane, J.K. et al., "Nicotine Up-Regulates Expression of Orexin and Its Receptors in Rat Brain" Endocrinology 2000 141(10): pp. 3623-3629.
Kang et al., "Amyloid-beta Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle", Science Express, 2009 , pp. 1-10.
Kang et al., "Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle", Science Express , 2009 , pp. 1-10.
Kirchgessner and Liu "Orexin synthesis and response in the gut", Neuron, 1999, 24 (4), pp. 941-951.
Kuduk et al., "Orexin receptor antagonists in development for Insomnia and CNS disorders", Annual Reports in medicinal Chemistry, 2013, 48, 73-87.
Kuduk et al., "Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant", Bioorganic & Medicinal Chemistry Letters, Apr. 2014, 24, 1784-1789.
Kuehn et al., "Hormone may play role in triggering panic attacks", Journal of the American Medical Association, Feb. 10, 2010, 303, 6, 498.
Langmead et al. "Characterisation of the binding of (3H)-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor", British Journal of Pharmacology 2004, 141 (2), pp. 340-346.
Larsen, Design and Application of Prodrugs, Drug Design and Development 1991 (Krogsgaard-Larsen, et al., eds., Harwood Academic Publishers.
Lawrence, et al., "The orexin system regulates alcohol-seeking in rats" British Journal of Pharmacology 2006, 148(6) pp. 752-759.
Lebold et al., "Selective orexin receptor antagonists", Bioorganic & Medicinal Chemistry Letters, Sep. 2013, 23, 4761-4769.
Lee, "Discharge of Identified Orexin/Hypocretin Neurons across the Sleep-Walking Cycle", J. Neuroscience, Jul. 2005, 25(8), 6716-6720.
Leman et al., "Role of orexin in the unpredictable chronic mild stress model of depression in mice", European Neuropsychopharmacology, Oct. 2012, 22, S2, S146, Abstract S.27.04.
Li et al., "Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders", Current Psychiatry Reports, Jan. 1, 2016, 18, 1, 1-12.
Lin et al. "The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene", Cell 1999, 98, pp. 365-376.
Lovenberg et al., "Selective Orexin-2 Receptor Antagonism as Adjunctive Therapy for Insomnia in Depression", Neuropsychopharmacology, Dec. 2013, 38, S2, S543-S544.
Malherbe et al. "Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist comparison with selective OX1 and OX2 antagonists", Molecular Pharmacology 2009, 76(3) pp. 618-631.
Malherbe et al. "Biochemical and electrophysiological characterization of almorexent, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists", Molecular Pharmacology 2009, 76(3) pp. 618-631.
Malherbe, P. et al., Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX.sub.2 Receptor, British Journal of Pharmacology 2009 156:1326-1341.
Malherbe, P. et al., Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 Receptor, British Journal of Pharmacology 2009 156:1326-1341.
Mang et al., "The Dual Orexin Receptor Antagonist Almorexant Induces Sleep and Decreases Orexin-Induced Locomotion by Blocking Orexin 2 Receptors", Sleep, Dec. 2012, 35(12), 1625-1635.
Marcus et al., "Differential Expression of Orexin Receptors 1 and 2 in the Rat Brain", Journal of Comparative Neurology, Jun. 2001, 435, 6-25.
McElhinny Jr. et al., "Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confounding effects on in vivo and in vitro studies", Bioorganic & Medicinal Chemistry Letters, Nov. 2012, 22, 6661-6664.
Mercer et al., "Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)", Bioorganic & Medicinal Chemistry Letters, Dec. 2013, 23, 6620-6624.
Micheli et al., "2-Methyl-3-furany1-4H-1,2,4-triazol-3-ylthioamides: A new class of selective orexin 2 antagonists", Bioorganic & Medicinal Chemistry Letters, Nov. 2010, 20, 6405-6407.
Michelson et al., "Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial", The Lancet, May 2014, 13, 461-471.
Mignot & Thorsby "Narcolepsy and the HLA System", New England J. Med. 2001, 344 (9), pp. 692.
Mignot et al. "Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups", Am. J. Hum. Genet. 2001, 68 (3), pp. 686-699.
Mignot et al., "Narcolepsy and the HLA System", New England J. Med., Mar. 2001, 344 (9), 692.
Moffitt et al., "Depression and generalized anxiety disorder. Cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years", Arch Gen. Psychiatry, Jun. 2007, 64, 651-660.
Nakamura at al. "Orexin-induced hyperlocomotion end stereotypy are mediated by the dopaminergic system", Brain Res. 2000, 873 (1) pp. 181-187.
Nakamura et al. "Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system", Brain Res. 200, 873 (1), pp. 181-187.
Nambu et al., "Distribution of orexin neurons in the adult rat brain", Brain Research, May 1999, 827, 243-260.
Nollet et al., "Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression", Neuropharmacology, Jul.-Aug. 2011, 61(1-2), 336-346.
Nollet et al., "Neurogenesis-Independent Antidepressant-Like Effects on Behavior and Stress Axis Response of a Dual Orexin Receptor Antagonists in a Rodent Model of Depression", Neuropsychopharmacology, Sep. 2012, 37, 2210-2221.
Nollet et al., "Role of Orexin in the Pathophysiology of Depression: Potential for Pharmacological Intervention", CNS Drugs, Jun. 2013, 27(6), 411-422.
Oi et al., "Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor", Journal of Medicinal Chemistry, Jul. 2013, 56, 6371-6385.
P. Bonaventure et al., Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J. Pharmacol. Exp. Ther., Aug. 4, 2015, vol. 354, No. 3, pp. 471-482.
Panksepp et al., "Dynorphin and orexin interactions in the development and expression of depression-related anhedonia", Neuropsychopharmacology, Dec. 2011, 36, S1, S432-S433, Abstract 196.
Paulekuhn, "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database", J. Med. Chem., Dec. 2007, 50, 6665-6672.
Paulekuhn, G. et al., "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book database", J. Med. Chem, 2007 50:6665-6672.
Perrey et al., "Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists", Bioorganic & Medicinal Chemistry Letters, May 2011, 21, 2980-2985.
Perrey et al., "Substituted Tetrahydroisoquinolines as Selective Antagonists for the Orexin 1 Receptor", Journal of Medicinal Chemistry, Sep. 2013, 56, 6901-6916.
Peyron et al, "Neurons Containing Hypocretin (Orexin) Project to Multiple Neuronal Systems", Journal of Neuroscience, Dec. 1998, 18(23), 9996-10015.
Peyron et al. "A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains", Nature Med. 2000, 6 (9), pp. 991-997.
Peyron et al. "Neurons containing hypocretin (Orexin) project to multiple neuronal systems" J. Neurosci., 1998, 18(23), pp. 9996-10015.
Piper et al. "The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats", European Journal of Neuroscience, 2000, 12 (2), pp. 726-730.
Piper et al. "The novel brain neuropeptide, orexino-A, modulates the sleep-wake cycle of rats", European Journal of Neuroscience, 2000, 12 (2), pp. 726-730.
Porter et al., "1,3-Biarylureas as Selective Non-peptide Antagonists of the Orexin-1 Receptor", Bioorganic & Medicinal Chemistry Letters, Jul. 2001, 11, 1907-1910.
Renzulli et al., "Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans", Drug Metabolism and Disposition, Feb. 2011, 39(2), 215-227.
Richards, J.K. et al., "Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats" Psychopharmacology (2008) 199:109-117.
Richards, J.K., et al., "Inhibition of orexin-1/hypocretin-1 receptors inhibits yohlmbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats" Psychopharmacology 2008, 199(1),pp. 109-117.
Robinson, "Discovery of the Hemifumarate and (Alpha)-L-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group", J. Med. Chem., Jan. 1996, 39(1), 10-18.
Robinson, R. et al., "Discovery of the Hemifumarate and (α-L-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindone: Prodrugs for the Enolic OH Group" J. Med. Chem. 1996 39 10-18.
Roecker et al., "Discovery of 5″-Chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2′:5′,3″terpyridine-3′-carboxamide (MK-1064): A Selective Orexin 2 Receptor Antagonist (2-SORA) for the Treatment of Insomnia", Chem Med Chem, Feb. 2014, 9, 311-322.
Sakurai, T. "Orexins and orexin receptors: implication in feeding behavior" Regulatory Peptides 1999, 85(1): pp. 25-30.
Sakurai, T. et al., "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein coupled receptors that regulate feeding behavior" Cell, Feb. 1998, 92(4), 573-585.
Sakurai, T. et al., "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior" Cell 1998, 92(4): pp. 573-585.
Sakurai, T., "The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness", 2007, Nature Reviews Neuroscience, 8(3):pp 171-181.
Samson et al. "Cardiovascular regulatory actions of the hypocretins in brain", Brain Res., 1999, 831: pp. 248-253.
Scammell et al., "Orexin Receptors: Pharmacology and Therapeutic Opportunities", Annual Review of Pharmacology and Toxicology, Feb. 2011, 51, 243-266.
Schneider, E. R., "Orexigenic peptides and alcohol intake: differential effects of orexin, gafanin, and ghrelin" Alcoholism: Clinical & Experimental Research 2007, 31(11):pp. 1858-1865.
Schneider, E. R., "Orexigenic peptides and alcohol intake: differential effects of orexin, galanin, and ghrelin" Alcoholism: Clinical & Experimental Research 2007, 31(11):pp. 1858-1865.
Scott et al., "Hcrtr1 and 2 signaling differentially regulates depression-like behaviors", Behavioural Brain Research, Sep. 23, 2011, 222, 2, 289-294.
Shan, D. et al., "Prodrug Strategies Based on the Intramolecular Cyclization Reactions" J. Pharm. Sci. 1997 86(7) 765-767.
Shan, D. et al., "Prodrug Strategies Based on the Intramolecular Cyclization Reactions" J. Pharm. Sci., Jul. 1997, 86(7), 765-767.
Shirasaka et al."Sympathetic and cardiovascular actions of orexins in conscious rats", Am. J. Physio., 1999, 277. pp. R1780-R1785.
Shirasaka et al."Sympathetic and cardiovascular actions of orexins in conscious rats", Am. J. Physiol., 1999, 277, pp. R1780-R1785.
Sifferlen et al., "Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1", Bioorganic & Medicinal Chemistry Letters, 24, Feb. 2014, 1201-1208.
Sifferlen et al., "Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists", Bioorganic & Medicinal Chemistry Letters, Mar. 2010, 20, 1539-1542.
Sifferlen et al., "Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2", Bioorganic & Medicinal Chemistry Letters, Jul. 2013, 23, 3857-3863.
Sifferlen et al., "Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a ]pyrazine derivatives as dual orexin receptor antagonists. Part 1", Bioorganic & Medicinal Chemistry Letters, Apr. 2013, 23, 2212-2216.
Smart et al., "Orexins and the treatment of obesity", European Journal of Pharmacology, Apr. 2002,440, 199-212.
Smart et al., "SB-334867-A: the first selective orexin-1 receptor antagonist", British Journal of Pharmacology, Mar. 2001, 132, 1179-1182.
Srinivasan et al., "Orexin Receptors Modulate Yohimbine-Induced Reinstatement Of Ethanol Seeking And Gabaergic Transmission In The Central Amygdala", Alcoholism Clinical and Experimental Research, Jun. 2012, 36, S1, 116A.
Staner et al., "Comorbidity of insomnia and depression", Sleep Medicine Reviews, Feb. 2010, 14, 46-65.
Stasi et al., "Discovery, synthesis, selectivity modulation and DMPK characterization of 5- azaspiro[2.4]heptanes as potent orexin receptor antagonists", Bioorganic & Medicinal Chemistry Letters, May 2013, 23, 2653-2658.
Steiner et al. "Discovery and Characterization of ACT-335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist", Chem Med Chem, Jun. 2013, 8, 898-903.
Steiner et al., "Opportunities and perspectives or developing orexin receptor antagonists", Frontiers in Science, Jun. 2014, vol. 8, Article 158, 1-2.
Steiner et al., "The brain orexin system and almorexant in fear-conditioned startle reactions in the rat", Psychopharmacology, Oct. 2012, 223, 465-475.
Sutcliffe et al., "The hypocretins: setting the arousal threshold", Nature Reviews Neuroscience, May 2002, 3, 339-349.
T.E. Scammell et al., 51 Annual Review of Pharmacology and Toxicology, 243-266 (2011).
Takahashi et al."Stimulation of gastric acid secretion by centrally administered orexin-A in conscious rats", Biochem. Biophys. Res. Commun., 1999, 254 (3), pp. 623-627.
Takahashi, "Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse", Neuroscience, May 2008, 153, 860-870.
Trivedi et al., "Distribution of orexin receptor mRNA in the rat brain", FEBS Letters, Sep. 1998, 438, 71-75.
Uno, "P.1.k.037 Prescription survey of orexin receptor antagonist suvorexant", European Neuropsychopharmacology, Sep. 2015, vol. 25, Supplement 2, S373-S374.
Ursin et al., "Cognitive activation theory of stress (CATS)", Neuroscience and Biobehavioral Rev, May 2010, 34, 877-881.
Ursin et al., "The cognitive activation theory of stress", Psychoneuroendocrinology, Jun. 2004, 29, 567-592.
Van Den Pohl, "Hypothalamic hypocretin (orexin): Robust innervation of the spinal cord" J. Neurosci., 1999, 19(8), pp. 3171-3182.
Watson, "Rethinking the mood and anxiety disorders: a quantitative hierarchical model for DSM-V", J Abnorm Psychol, Nov. 1, 2005, 114(4), 522-536.
Whitman et al., "Discovery of a Potent, CNS-Penetrant Orexin Receptor Antagonist Based on an N,N-Disubstituted-1,4-diazepane Scaffold that Promotes Sleep in Rats", Chem Med Chem, Jul. 2009, 4, 1069-1074.
Winrow et al., "Discovery and development of orexin receptor antagonists as therapeutics for insomnia", British Journal of Pharmacology, Jan. 2014, 171, 283-293.
Winrow, C. J., "Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure" Neuropharmacology 2010, 58(1):pp. 185-194.
Winsky-Sommerer et al., "Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response", J Neuroscience, Dec. 2004, 24(50), 11439-11448.
Yamanaka et al.", Orexins activate histaminergic neurons via the orexin 2 receptor", Biochem. Biophys. Res. Comm., Feb. 2002, 290 (4), 1237-1245.
Yamanaka et al."Orexins activate histaminergic neurons via the orexin 2 receptor", Biochem. Biophys. Res. Comm. 2002, 290 (4), pp. 1237-1245.
Yeoh et al. "Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls", Frontiers in Neuroscience, Feb. 25, 2014, 8, Article No. 36, 12 pages.

Also Published As

Publication number Publication date
CN102781942B (zh) 2015-09-23
KR20170136645A (ko) 2017-12-11
PL3093291T3 (pl) 2019-11-29
EP2491038A1 (en) 2012-08-29
SI3093291T1 (sl) 2019-08-30
CY1117743T1 (el) 2017-05-17
HRP20191220T1 (hr) 2019-10-18
LT3093291T (lt) 2019-07-10
US8653263B2 (en) 2014-02-18
NZ599629A (en) 2013-12-20
US20170129901A1 (en) 2017-05-11
EP3093291A1 (en) 2016-11-16
IL219234A0 (en) 2012-06-28
US20210347781A1 (en) 2021-11-11
EA022766B1 (ru) 2016-02-29
CR20120273A (es) 2012-10-25
US20120208812A1 (en) 2012-08-16
US20150335651A1 (en) 2015-11-26
UY32966A (es) 2011-04-29
EP3581575A1 (en) 2019-12-18
HRP20160781T1 (hr) 2016-09-23
KR20120105449A (ko) 2012-09-25
RS59004B1 (sr) 2019-08-30
SMT201600216B (it) 2016-08-31
SI2491038T1 (sl) 2016-08-31
AU2015242975A1 (en) 2015-11-05
PT2491038T (pt) 2016-07-14
ES2735411T3 (es) 2019-12-18
AU2010310595B2 (en) 2015-07-16
HK1175463A1 (zh) 2013-07-05
US11059828B2 (en) 2021-07-13
US11667644B2 (en) 2023-06-06
TR201910327T4 (tr) 2019-07-22
CO6541572A2 (es) 2012-10-16
CN102781942A (zh) 2012-11-14
JOP20180019B1 (ar) 2023-09-17
HUE028650T2 (en) 2016-12-28
ME03452B (me) 2020-01-20
WO2011050198A1 (en) 2011-04-28
ES2585806T3 (es) 2016-10-10
NI201200062A (es) 2013-04-19
KR20170135989A (ko) 2017-12-08
US20200048263A1 (en) 2020-02-13
BR112012010820A2 (pt) 2016-04-05
BR112012010820B1 (pt) 2021-09-14
TWI481613B (zh) 2015-04-21
UA107812C2 (en) 2015-02-25
PT3093291T (pt) 2019-07-25
ME02437B (me) 2016-09-20
EP2491038B1 (en) 2016-04-06
HK1231463A1 (zh) 2017-12-22
PL2491038T3 (pl) 2016-10-31
US20240109901A1 (en) 2024-04-04
US9079911B2 (en) 2015-07-14
AR078731A1 (es) 2011-11-30
MX2012004753A (es) 2012-09-07
CA2778484A1 (en) 2011-04-28
IL219234A (en) 2015-02-26
JO3267B1 (ar) 2018-09-16
EA201270591A1 (ru) 2012-11-30
HUE043962T2 (hu) 2019-09-30
AU2010310595A1 (en) 2012-05-17
JP5759470B2 (ja) 2015-08-05
DK2491038T3 (da) 2016-07-18
JOP20180019A1 (ar) 2019-01-30
DK3093291T3 (da) 2019-07-29
ECSP12011908A (es) 2012-07-31
KR101859409B1 (ko) 2018-05-18
CL2010001162A1 (es) 2011-04-08
TW201217377A (en) 2012-05-01
KR101859400B1 (ko) 2018-05-18
CY1121848T1 (el) 2020-07-31
PE20110404A1 (es) 2011-07-08
CA2778484C (en) 2018-07-31
AR114667A2 (es) 2020-09-30
RS54945B1 (sr) 2016-11-30
JP2013508403A (ja) 2013-03-07
AU2015242975B2 (en) 2017-06-01
US20140179697A1 (en) 2014-06-26
EP3093291B1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
US11667644B2 (en) Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US9586962B2 (en) Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
US8680275B2 (en) Fused heterocyclic compounds as orexin receptor modulators
US9062044B2 (en) Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY